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ABSTRACT OF THE DISSERTATION
Proteomic Profiling of Serum Derived Exosomes from Prostate Cancer Patients
by
David Turay
Doctor of Philosophy, Graduate Program in Anatomy
Loma Linda University, March 2016
Dr. Nathan R. Wall, Chairperson
Touted among the major achievements in the diagnosis and management of
Prostate cancer (PCa) in the past few decades has been, the dramatic decline of men with
advanced/metastatic PCa at diagnosis coupled with a significant improvement ( >90%)
in the five and ten year survival rates of the disease. Non-palpable PCa (potentially
clinically treatable disease) now accounts for 70-80% of all newly diagnosed cases of
PCa. Preceding these changes by about a decade was the introduction of Prostatic
Specific Antigen (PSA) into clinical practice; first as biomarker for monitoring response
to therapy and subsequently as a complementary screening tool. It is not surprising then
that a cause-effect relationship has been suggested. Like a double-edged sword, the use
of PSA as a screening tool has also been blamed for the rise of unnecessary prostate
related invasive procedures including biopsies and surgeries. Some of the documented
criticisms of PSA include its lack of specificity (elevated in inflammation) for PCa and
the difficulty of establishing a cut-off value that is highly sensitive and specific for the
disease. It is estimated that perhaps up to half of the PCa diagnosis are patients whose
tumors would have been clinically undetectable had PSA not been included in the
screening process. The dissatisfaction with PSA has created opportunities to search for
novel biomarkers for screening and monitoring of treatment in PCa. Some of the more
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novel biomarkers that have been examined as potential replacements for PSA are the
RNA product prostate cancer antigen-3 (PCA 3), the enzyme alpha methylacyl-CoA, and
the gene fusion product TMPRSS2-ERG. More recently Zhang, Casiano and colleagues
described an increased predominance of autoantibodies to Cyclin-B1 in the sera of PCa
patients compared to controls with Benign Prostatic Hyperplasia (BPH). All these efforts
are in different stages of maturity but yet to have ground breaking clinical impact.
We hereby examined the role of exosomes in PCa and a qualitative profile of its
proteomic composition. The higher levels of circulating exosomes in sera of PCa patients
is directly prostate-derived and could be stress-induced as the non-cancer prostate stroma
and the immune system interact with neoplastic cells. This could be reflected in some of
the similarities in the proteomic profile of serum-derived exosomes and exosomes
derived from direct PCa in vitro cell line cultures. Moreover, PCa has a higher incidence
and a greater disease severity in non-Hispanic African Americans and this difference in
disease biology can be reflected in the difference in the proteomic profile of exosomes
across ethnicities/races. Serum exosomes originate from a diverse population of normal,
neoplastic or inflammatory cells. Tumors do shed membrane vesicles directly into serum
or extracellular space. These vesicles are referred to as tumor derived exosomes (TEX).
Our overall objective was to use a seroproteomics approach focused on profiling serum
exosomes in PCa patients. This profile would then be compared with that of non-cancer
patients in an effort to identify proteins unique to cancer patients. A comparative study
across racial groups will help us begin to identify possible protein markers/players
involved in determining disease aggressiveness. The project hopes to one day fill the gap
of the lack of biomarker identification in PCa patients and perhaps give us potential

xv

therapeutic targets to help lower morbidity in the black and indeed all cohorts of patients.
It builds on preliminary data indicating that PCa patient sera have exosomes containing
stress survival and cancer related proteins.
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CHAPTER 1
LOCALIZATION AND UP-REGULATION OF SURVIVIN IN CANCER
HEALTH DISPARITIES: A CLINICAL PERSPECTIVE.

Published:
Khan S, Ferguson Bennit H, Valenzuela MMA, Turay D, Diaz Osterman CJ, Moyron
RB, Esebanmen GE, Ashok A, Wall NR. Localization and up regulation of Survivin in
cancer health disparities: a clinical perspective. Biologics: Targets and Therapy, 9: 57-67,
2015.
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Abstract
Survivin is one of the most important members of the inhibitors of apoptosis
(IAP) protein family as it is expressed in most human cancers but is absent in normal,
differentiated tissues. Lending to its importance, Survivin has proven associations with
apoptosis and cell cycle control and has more recently been shown to modulate the tumor
microenvironment and immune evasion as a result of its extracellular localization. Up
regulation of Survivin has been found in many cancers including breast, prostate,
pancreatic, and hematological malignancies and may prove to be associated with the
advanced presentation, poorer prognosis and lower survival rates observed in ethnically
diverse populations.

Key Words: Survivin, cancer, exosomes, health disparity
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Introduction
Cancer is a major public health problem in the United States and the world.
Recent epidemiological statistics indicate that cancer will develop in one in three women
and one in two men in the US over their lifetime.(Siegel et al., 2013) The three most
common cancers among males are prostate, colorectal and melanoma of the skin, and
among females, breast, uterine corpus and colorectal.(Sharp et al., 2014) Although
deaths attributed to cancer have declined among both Caucasians and African Americans,
African Americans continue to suffer a greater burden for each of the most common
types of cancer.(Siegel et al., 2013) This discrepancy recorded among cancer patients
from different ethnicities is termed cancer health disparity. The National Cancer Institute
(NCI) defines cancer health disparity as an adverse difference in cancer incidence (new
cases), cancer prevalence (all existing cases), cancer death (mortality), cancer
survivorship, and burden of cancer or related health conditions that exist among specific
population groups.(Siegel et al., 2013) When investigating the factors that contribute to
cancer health disparities, the most obvious are access to health care and socioeconomic
status.(Beydoun & Beydoun, 2008, Guessous et al., 2010, Jadav et al., 2015) However,
evidence exists that dietary fat can influence carcinogenesis.(Tsai & Giovannucci, 2012)
In 1982, the US National Academy of Sciences committee on Diet, Nutrition and Cancer,
using both epidemiological and experimental data, concluded that a causal relationship
between fat intake and the occurrence of cancer exists.(Council, 1982) However, the
strongest evidence that environmental factors give rise to an etiology of cancer comes
from the studies of cancer incidence in different ethnic populations and their migrations
and lifestyle habits. Specifically, the adoption of a Westernized diet appears causal in the
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significant increase in annual deaths, in native Japanese, from colon,(Takachi et al.,
2011) breast(Kono, 2010) and pancreatic cancers(Kasuga et al., 2013) upon their moving
from Japan to the United States. In addition, experimental animal studies agree that both
specific and non-specific evidence exists for the occurrence of cancer being strongly
associated with consumption of a diet high in fat.(Guthrie & Carroll, 1999)
Contradictory studies also exist in which lifestyle factors in cancer incidence have been
described. Whereas years smoking and number of cigarettes smoked had a correlation
with increased incidence of pancreatic cancer, there was no correlation with pancreatic
cancer and body mass index, physical activity, alcohol, coffee and green tea
consumption.(Nakamura et al., 2011)
Early detection is important in cancer discovery, treatment and survival. In order
to better understand cancer incidence and mortality in diverse populations it has become
imperative that we identify and then characterize markers of cancer development and
progression to include both pathways and molecular mechanisms associated with these
disparities. Given the strong link between cancer incidence, oxidative stress and diets
high in fat,(De Pergola & Silvestris, 2013) we must map these associations and identify
the survival entities and pathways as potential targets. A long-term goal in health
disparities research is to understand how an increase in oxidative stress will ultimately
promote cancer cell resistance to therapy-induced death and how to overcome this
resistance.
Survivin is an important member of the inhibitors of apoptosis (IAP) protein
family because its tumor specific expression is unique out of all of the human gene
products.(Reed, 2001) Survivin expression is evident during embryonic and fetal
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development but not in terminally differentiated tissue.(Li et al., 1998) It is expressed in
virtually all of the different types of human cancers (Table I), making Survivin an
alluring protein in the study of carcinogenesis.(Andersen et al., 2007) Survivin is
referred to as a bifunctional protein, having essential roles in inhibiting apoptosis and
controlling proper cell division.(Altieri, 2003) In our most recent work we have begun to
refer to Survivin as a multifunctional protein as it does much more, to include controlling
diverse cellular functions, including surveillance checkpoints, suppression of cell death,
the regulation of mitosis, and adaptation to unfavorable environments.(Altieri, 2003,
2006)

Localization of Survivin
The multifaceted functionality of Survivin is still being intensely scrutinized, and
it appears that protein compartmentalization may be important. Survivin has been shown
to localize in mitochondria, where it modulates tumor cell apoptosis similar to the Bcl-2
family.(Dohi, Beltrami, et al., 2004b) Its localization to nucleus and cytosol confers its
role in mitosis regulation and apoptosis inhibition, respectively.(Fortugno et al., 2002)
Furthermore, we have identified the existence of Survivin extracellularly, contained in
small membrane bound vesicles known as exosomes (Figure 1), and have shown that
exosome-bound Survivin protein can be secreted by cancer cells to be taken up by
surrounding cells, producing a field effect that confers a general stress-survival
phenotype.(Khan et al., 2009, Khan S et al., 2011, Webber et al., 2015).
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Table: Influence of Survivin on Clinical Prognosis.
Cancer type

Survivin
expression

Reference

1. Breast cancer

On
prognosis/staging
of the disease
Good to poor

Moderate
to high

2. Prostate cancer

Fair to poor

3. Pancreatic
cancer
4. Leukemia

Poor

Moderate
to high
High

Kalla Singh 2010, Adamkov
2012, Rexhepaj 2010, Xu
2012, Dedić Plavetić 2013,
Span 2006, Li 2004, Boidot
2009, Khan 2014
Zaffaroni 2005, Shariat 2004,
Koike 2008, Zhang 2009
Xie 2013

Good to poor

Low to
high

5. Other cancers

Good to poor

Moderate
to high
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Fulda 2009, Kamihira 2001,
Park 2011 , Kelly 2011,
Troeger 2007, Esh 2011, Tyner
2012, Ahmed 2012, Morrison
2012, Grzybowska-Izydorczyk
2010, Carter 2012, Small 2010
Waligorska-Stachura 2009

Figure 1. Exosomes play important roles in intercellular communication. A tumor
cell communicates with the tumor microenvironment and may be able to affect cancer cell
aggressiveness as a result of the protein, RNA and/or miRNA payload found within. One
potentially important protein to the proliferative, invasive or therapy resistance nature of
the tumor is Survivin which has been found released from cancer cells in exosomes.
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Consistent with Survivin’s association with unfavorable clinicopathological parameters,
extracellular trafficking of Survivin throughout the tumor microenvironment could be
responsible for augmenting the aggressive status of a tumor while prohibiting or
minimizing therapeutic results.(Li F et al., 1999, Li & Ling, 2006, Khan et al., 2009)
This review focuses on the multifaceted roles of Survivin in cancer biology, its cellular
localization and its cancer health disparity-specific up regulation, specifically in breast,
prostate, pancreas and hematological cancers.

Nuclear Survivin as a Cell Cycle Regulator
Nuclear Survivin is known to be a cell cycle associated protein. Investigations of
cell division regulation during the depletion of Survivin by siRNA demonstrated an
increase in mitotic arrest and chromosomal misalignment. Furthermore, this study
confirmed that Survivin is involved in microtubule assembly and centromere stabilization
during mitosis.(Yang et al., 2004) Survivin’s role in mitosis regulation is associated with
its involvement in the chromosomal packaging complex and its contribution to the
formation of the mitotic spindle.(Altieri, 2008, Church & Talbot, 2012) IAP family
proteins cIAP2 and Survivin have been shown to dramatically increase upon exposure to
hypoxia.(Dong et al., 2001, Dohi, Okada, et al., 2004) Furthermore, survivin’s promoter
has been shown to contain 3 putative HIF-1 binding or response elements.(Zagorska &
Dulak, 2004) Nuclear Survivin was found to be distinctly involved in the prognosis of
different cancers as will be discussed in our specific cancers section.
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Cytoplasmic/Mitochondrial Survivin as an Apoptosis Inhibitor
Survivin’s ability to interfere with cellular death pathways appears to reside in the
cell’s cytoplasm. Survivin localizes to the mitochondria(Dohi, Beltrami, et al., 2004a)
and therefore may provide, like Bcl-2, a role in mitochondrial stability. Cellular stress
was shown to modulate the expression and localization of Survivin with hypoxia-induced
Survivin found exclusively in the mitochondria. Furthermore, upon apoptotic
stimulation, mitochondrial Survivin is rapidly released to the cytosol where its
cytoprotective effects prevent the activation of the initiator caspase 9.(Dohi, Beltrami, et
al., 2004a)
Early studies showed that Survivin and XIAP protected cells from undergoing
caspase-dependent apoptosis. Subsequently, in vitro binding experiments showed that
Survivin, like XIAP and other IAPs, bound to the terminal effector cell death proteases,
caspase 3 and 7, but not to initiator caspase 8.(Tamm et al., 1998) Controversy in the
field arose when a study by the Altieri group showed that Survivin did not inhibit caspase
3 activity and where recombinant Survivin failed to decrease recombinant caspase 3
activity in vitro.(Banks et al., 2000) Current evidence suggests that Survivin acts on
caspases in an indirect manner by binding to the hepatitis B X interacting protein
(HBXIP) and forming a complex with pro-caspase 9, inhibiting the apoptosome
formation.(Marusawa et al., 2003) This Survivin-HBXIP complex, not individual
Survivin or HBXIP proteins, binds to pro-caspase 9 and works to prevent recruitment of
apoptosis activating factor 1 (Apaf1) thus suppressing intrinsic apoptosis. In addition,
Survivin binds to and regulates the stability of XIAP, which is a direct caspase 3 and 9
inhibitor.(Church & Talbot, 2012) More specifically, the formation of a Survivin-XIAP
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complex promotes increased XIAP stability, protecting XIAP from proteasomal
degradation, resulting in a facilitated inhibition of caspase-dependent cell death.(Dohi,
Okada, et al., 2004)

Extracellular Survivin as a Modulator of Tumor Microenvironment
Survivin has recently been shown to exist in the extracellular space,(Khan et al.,
2009) via 40-100 nm membrane vesicles called exosomes.(Khan S et al., 2011) Various
cell types, such as B- and T- lymphocytes, dendritic cells, neurons, intestinal epithelial
cells, as well as tumor cells release exosomes.(Denzer K et al., 2000, Keller S et al.,
2006, Simpson RJ et al., 2009, Greening et al., 2015) In particular, it has been shown
that both human and mouse tumor cells release tumor cell-derived exosomes (TEX)
constitutively.(Wolfers J et al., 2001) Additionally, specific protein content found both
on and within TEX give an indication of their functional and biological roles, and their
cell of origin, making TEX excellent biomarkers.(Zitvogel L et al., 1998, Andre et al.,
2002, Wieckowski E & TL, 2006, Aleckovic & Kang, 2015) Early detection, aggressive
determination, and therapeutic efficacy may one day be possible through the use of these
exosomes and their contents.
Our lab has shown that the extracellular pool of Survivin has the ability to cause
neighboring cancer cells to increase resistance to therapy, rapidly proliferate and acquire
an increased potential to become invasive in vitro,(Khan et al., 2009) providing a
protective role to the neighboring tumor cells.(Khan S et al., 2011) The ability of
extracellular Survivin to cause these effects in the surrounding cancer cells correlates
with the fact that Survivin overexpression is observed in virtually every human cancer
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type.(Altieri DC, 2003a) TEX may also be used as a tool to detect malignant
conditions.(Aleckovic & Kang, 2015) Serum taken from cancer patients has an increased
level of TEX,(Ginestra A et al., 1998, Ginestra A et al., 1999) which has a positive
correlation with the progression of the tumor.(Khan S et al., 2011) In addition to serum,
TEX were shown to be isolated from malignant tumor fluids, urine,(Nilsson et al., 2009,
Rolfo et al., 2014) ascites fluids(Adams et al., 2005, Shender et al., 2014) and pleural
effusions.(Andre et al., 2002, Park et al., 2013) We have recently shown that exosomal
Survivin may be a useful tool for early detection, diagnosis, and even monitoring prostate
cancer progression.(Khan et al., 2012) Newly diagnosed and advanced prostate cancer
patients with high or low-grade cancer had significantly higher levels of exosomal
Survivin compared to control subjects or patients with pre-inflammatory benign prostatic
hyperplasia (BPH).(Khan et al., 2012)

Survivin in Cancer Immunity Evasion
Survivin has been ascribed multiple roles not only in malignancy, but also in
immunity and differentiation.(Zangemeister-Wittke & Simon, 2004) Survivin has been
shown to be essential for T-cell maturation, homeostasis and proliferation at various
stages of development.(Xing et al., 2004) It has also been shown to modulate peripheral
blood leukocytes (PBL) when in the extracellular space by binding to leukocytes, thereby
inducing molecular processes implicated in the pathogenesis of inflammation.(Mera et
al., 2008) On the basis of the literature and our data, Survivin may be said to exhibit
duplicity in cancer immunity as it can act as a tumor associated antigen, or modulate
immune environment to permit tumor growth.
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Recently, an artificial antigen-presenting cell, developed to study anti-Survivin
CD4+ T-cell responses in cancer patients, was shown to elicit both Th1 and Th2
responses against Survivin. The level of avidity was appropriate to recognize tumor
cells.(Tanaka et al., 2011) Previously, constructed DNA-peptide complexes (mimovirus)
of Survivin epitopes, have been shown to stimulate strong cytotoxic T lymphocyte
(CTL)-mediated long-term memory of murine immune response and exact a high antitumor effect in BALB/c mice.(Yang et al., 2008) Furthermore, a DNA construct
encoding a secreted version of Survivin, along with a plasmid coding for murine
granulocyte-macrophage colony-stimulating factor (GM-CSF) as a molecular adjuvant,
were observed to elicit humoral responses against Survivin in sera collected from mice.
IgG2a antibody was the prevalent antibody sub-class, thereby implicating the induction
of a Th1-CD4+ cellular response.(Lladser et al., 2006)
We have recently shown that when T-cell cultures were incubated with Survivin,
surface binding and intracellular uptake of Survivin by these T-cells occurred. Upon
further investigation, a Survivin-associated decreased proliferation was observed in these
T-cells. In addition, analysis of CTLs revealed a reduction in their functional
cytotoxicity. However, Treg (T-regulatory cell) function remained unaltered.
Importantly, the numbers of Th1 and Tc1 cells were significantly reduced, together with
the cytokines associated with them (IFN-γ and IL-2), while an increase in IL-4+, IL-5+
and IL-13+ T-cells was observed. These results suggest a skewing from a type 1 response,
which mediates immunity with cytokines that enhance cellular cytolytic activity and can
elicit an effective anti-tumor response to a type 2 T-cell response which does not lead to
tumor rejection and is frequently observed in cancer patients.(Wan, 2010, Amarnath et
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al., 2011, Pietra et al., 2012, Jutzy et al., 2013) The verification and molecular
mechanism underlying this Th cell plasticity is yet to be fully elucidated.

Cancer Specific Up Regulation of Survivin: Breast Cancer
Breast cancer is the second most common cancer type (following lung cancer) and
the most common cancer among women worldwide. It is estimated that in the United
States alone there are nearly 3 million women with diagnosed breast cancer and
approximately 227,000 more will be added to that number this year.(Siegel et al., 2013)
African American women are more likely than all other women to die from breast cancer
as their tumors often are discovered at a later, more advanced stage, leaving them fewer
treatment options.(Dehal et al., 2013, Johnson et al., 2013) There are several pathways
involved in breast cancer pathogenesis with pathways of tumor cell death playing an
important role in its development and maintenance. Among the proteins involved in cell
death/survival pathways, Survivin is one of the most studied. Using serial analysis of
gene expression (SAGE), Survivin was found to be the fourth highest expressed
transcript in a number of common cancers including breast cancers.(Velculescu et al.,
1999) In a study examining the interaction of the insulin-like growth factor II and
Survivin, Kalla Singh S et al, found that high IGF-II expression-regulation of Survivin
correlated and was significantly higher in African Americans than in Caucasians.(Kalla
Singh et al., 2010) In this study it was shown that IFG-II regulates Survivin, leading to
inhibition of mitochondrial membrane depolarization, cell survival and chemoresistance.
Furthermore, the effect of IGF-II and IGF-II siRNA on the expression of Bcl-2, Bcl-XL
and Survivin in African American and Caucasian breast cancer cells was measured. IGF-
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II expression was shown to be causative in the upregulation of these antiapoptotic
proteins, while IGF-II siRNA was prohibitive.(Kalla Singh et al., 2010) This intriguing
observation will require further investigation.
The different sub-cellular pools of Survivin in breast cancer appear to have
distinct functions. Adamkov et al, suggested that nuclear staining of Survivin antigen
could be used as a marker of the degree of neoplasia,(Adamkov et al., 2012) while
Rexhepaj et al, suggested that increased levels of nuclear Survivin are associated with a
proliferative phenotype.(Rexhepaj et al., 2010) One thing that is clear is that Survivin
plays a key role in the initiation and progression of breast cancer. High mRNA
expression was found to be an independent prognostic marker in breast cancer
patients(Xu et al., 2012) and Survivin up regulation significantly correlated to lymph
node involvement, tumor stage and histological type.(Dedić Plavetić et al., 2013) By
contrast, others have shown that high levels of its expression are associated with a
beneficial response to chemotherapy.(Span et al., 2006) This could be due to alternative
splicing of Survivin. Multiple studies demonstrate that alternative splicing patterns are
altered during cancer progression.(Li, 2004) Several different mechanisms contribute to
changes in the regulation of alternative splicing including stress, stimulation of receptors
by growth factors, cytokines, or hormones, etc. Survivin, to date, has six different
described variants with different apoptotic properties and intracellular localization
(Figure 2).(Necochea-Campion et al., 2013) Protein and mRNA levels of the pro- and
anti-apoptotic isoforms of Survivin correlate with cancer prognosis.(Boidot et al., 2009)
Early diagnosis of breast cancer is challenging due to a lack of serum biomarkers
and inadequate as it is performed through invasive means such as needle biopsy, scanning
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Figure 2. Splicing of the human survivin pre-mRNA produces six different splice
variants. With the exception of survivinand survivin-2B, survivin-WT, survivinΔEx3, survivin-3B, and survivinphenotypes. The survivin-2B has been shown to have either a favorable or unfavorable
association depending upon the cancer type it is expressed in, and survivinbe determined.
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and invasive pathological examination. Despite the availability of numerous diagnostic
and prognostic methods, there remains a need for an easy, sensitive and non-invasive way
to track tumor activity. We propose that through analysis of tumor exosomes and by
specifically assaying these exosomes for tumor-specific antigens such as Survivin, XIAP,
cIAP1/2, chaperone proteins such as HSP70 and 90, just such a biomarker discovery may
one day be realized. We have found an extracellular Survivin pool in serum exosomes in
prostate(Khan et al., 2012) and breast cancers.(Khan et al., 2014) In these breast cancer
patients’ sera, we found Survivin levels and exosome numbers to be significantly
increased over controls with a disparate expression of the Survivin splice variants similar
to that observed in tissues. It is important though that we recognize the possible
confounding factors such as co-morbidities, psychological complications, genetics, and
environmental exposures that could affect these results.

Cancer Specific Up Regulation of Survivin: Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer in men
and the second leading cause of male cancer deaths in the U.S., accounting for 238,590
new cases and 29,720 deaths in 2013.(Brawley, 2012b, Siegel et al., 2013) These
statistics have undergone minimal changes despite advances in screening and early
diagnosis and therefore still require a significant investment if prostate cancer is to be
defeated. As has recently been described by our colleagues, African American men have
a growing disparity in their prostate cancer incidence and mortality compared to other
ethnic groups,(Basu et al., 2011) and they present with the disease at a much younger age
than do Caucasian men which is a trait common in more aggressive cancers.(Hoffman et
al., 2001, Karami et al., 2007)

16

Survivin is expressed in prostate cancer and has been shown to be up regulated in
order to protect the prostate cancer microenvironment against apoptosis and oxidative
stress-induced damage.(Zaffaroni et al., 2005) Survivin therefore directly and/or
indirectly influences cell survival and death. Shariat et al., using immunohistochemistry,
compared Survivin protein expression in normal and malignant prostate tissue and lymph
node tissue from prostate cancer patients. There appeared to be a gradual but consistent
rise of Survivin expression from normal prostate specimens (36%), to prostate cancer
(71%), with the highest expression found in metastatic lymph nodes (81%).(Shariat et al.,
2004) Survivin expression therefore seemed to correlate with the degree of transition
from normal prostate epithelia to a more aggressive form of prostate cancer (metastatic
prostate cancer).
Our group recently looked at relative levels of Survivin in the sera of prostate
cancer patients and compared it to that of patients with BPH and from subjects with no
diagnosis of cancer or BPH.(Khan et al., 2012) Survivin levels proved to exhibit a
stronger correlation in our hands than prostate specific antigen (PSA) when it came to
distinguishing the two clinical conditions. We therefore propose that exosomal Survivin
evaluation should be given serious consideration as a plausible biomarker for early
detection of prostate cancer and perhaps could be used to monitor treatment efficacy and
disease recurrence. Higher levels of not only Survivin, but its splice variants 2B and 2α,
both in vitro and in tissue, seem to correlate with prostate cancer cell proliferation and a
more aggressive phenotype.(Koike et al., 2008) The intracellular compartment
localization of Survivin has been suggested to be of prognostic value. When tissues of
patients with locally advanced prostate cancer were stained and examined for Survivin,
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patients with higher levels of intranuclear Survivin exhibited improved survival, whereas
those with higher levels of cytoplasmic Survivin exhibited a poorer prognosis.(Zhang et
al., 2009)
In summary, Survivin, in prostate cancer has a dual role as an inhibitor of
apoptosis and cell cycle mediator. Its level of expression appears to correlate with the
progression from normal to indolent and to a more aggressive form of prostate cancer.
Our demonstration of exosomal Survivin in the plasma of patients with newly diagnosed
low-grade prostate cancer(Khan et al., 2012) provides a rationale for studies to
investigate the utility of exosomal Survivin as an early, easily measured biomarker for
prostate cancer diagnosis as well as a marker to monitor treatment efficacy and tumor
recurrence.

Cancer Specific Up Regulation of Survivin: Pancreatic Cancer
Cancer of the pancreas is the fourth most common cause of cancer death in men
and women in the United States. In 2013, an estimated 45,220 new cases and 38,460
deaths from pancreatic cancer occurred.(Siegel et al., 2013) It is a highly malignant
disease and lacks clear early warning signs or symptoms thus remaining silent in its
victims until it is well advanced. The vast majority of patients are not diagnosed until
stage III or IV and once diagnosed exhibit a median survival of 4-8 months with a 5-year
survival rate being <5%.(Lowenfels & Maisonneuve, 2006) Risk factors include gender,
age, diabetes, chronic pancreatitis, family history, smoking, alcohol abuse and possibly
diets high in fat.(Lowenfels & Maisonneuve, 2006) Early diagnosis continues to be the
greatest obstacle and there is an urgent need for screening biomarkers.
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Pancreatic cancer incidence in the United States is higher in African Americans
and Hispanics than in Caucasians.(Gordis, 1993, Woutersen et al., 1999) In a number of
recent studies, the risk factors in men (cigarette smoking and diabetes mellitus) and
women (moderate/heavy alcohol consumption and an elevated body mass index
(obesity)), explain almost the entire African American/non-Hispanic White disparity in
incidence. In the absence of these risk factors, pancreatic adenocarcinoma incidence
rates among African Americans do not exceed those of Caucasians from either men or
women.(Chang et al., 2005, Hayanga, 2005, Singal et al., 2012) In 2003, a group at the
Barbara Ann Karmanos Cancer Institute analyzed a group of pancreatic cancer patients
(166 African American, 244 Caucasian) for clinicopathologic characteristics of the
disease as well as immunohistochemical expression of commonly found pancreatic
cancer biomarkers: Fas, FasL, p21/waf-1, p27, p53 and Her2. They also investigated the
presence and types of K-ras mutations at codon 12.(Pernick et al., 2003) African
Americans were found to have significantly higher rates of K-ras mutations than did
Caucasians, and their treatment with chemotherapy or radiation therapy was also much
less effective than that recorded in Caucasians. African Americans more frequently than
Caucasians were found with positive surgical margins and many clinicopathologic
variables such as median survival, 5-year survival, and stage at presentation were
different. African Americans were less immunoreactive to Fas expression and had a
much stronger Her2 expression than did Caucasians.(Pernick et al., 2003)
As in prostate and breast cancer as previously discussed, epidemiological
evidence exists for a strong association between pancreatic cancer and a high
consumption of dietary fat. Dietary fat is made up of fatty acids and lipids that are
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metabolized into arachidonic acid. The key enzymes for arachidonic acid metabolism are
lipoxygenases (LOXs) and cyclooxygenases (COXs) which outside of dietary fat research
have been shown associated with the development and progression of pancreatic
cancer.(Ding et al., 2001) LOX and COX inhibitors prohibit the continued progression
of pancreatic cancer and induce intrinsic mitochondria-associated apoptotic cell
death.(Tong et al., 2002)
There have been numerous studies performed on the prognostic implications of
Survivin in pancreatic cancer. A high expression of Survivin was found to be related to
shorter survival in patients with resected pancreatic adenocarcinoma.(Xie et al., 2013) In
contrast, high nuclear levels of Survivin predicted better prognosis than cytoplasmic
Survivin.(Tonini et al., 2005) Furthermore, Sagol et al and Sun et al showed no
significant association between Survivin and long-term survival.(Sagol et al., 2005, Sun
et al., 2007) Targeting Survivin early on in the process could play an invaluable role in
preventing the progression to malignancy. In addition, a screening biomarker that could
potentially detect early stages of the disease is of utmost importance.

Cancer Specific Up Regulation of Survivin: Hematological Malignancies
Hematological malignancies such as leukemia, lymphoma, myeloma and
myelodysplastic syndromes affect the bone marrow, the blood cells, the lymph nodes and
other parts of the lymphatic system. These pathologies are interrelated, likely the result
of acquired changes to the DNA of a single stem cell. Approximately 140,000 people
will be diagnosed with leukemia, lymphoma or myeloma, accounting for approximately 9
% of all new cancers diagnosed each year in the United States.(Society, 2012) Of
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particular interest is multiple myeloma (MM), which accounts for approximately 10 % of
all hematologic malignancies diagnosed in the United States annually.(Pulte et al., 2012)
Among the hematological malignancies, MM is known to affect individuals from
ethnically diverse populations in a disparate manner.
In accordance with reports for many types of solid tumors,(Church & Talbot,
2012, Waligorska-Stachura et al., 2012) cancer specific up regulation of Survivin also
occurs in hematological malignancies,(Fulda, 2009, 2012) though to date there have been
no published reports taking ethnicity into account. In hematological cancers, expression
of Survivin is associated with poor clinical outcomes and resistance to
chemotherapy.(Adida et al., 2000, Kamihira et al., 2001, Kelly, 2011, Park et al., 2011)
Survivin expression levels are linked to risk of early relapse in pediatric B-cell acute
lymphoblastic leukemia (ALL)(Troeger et al., 2007, A. Esh, 2011, Tyner et al., 2012)
and to tumor aggressiveness(Ahmed et al., 2012) and chemoresistance in adult
ALL.(Morrison et al., 2012)
High levels of Survivin expression have also been linked to cell proliferation and
antiapoptotic characteristics in chronic myelogenous leukemia (CML),(Wang et al.,
2005) and chronic lymphocytic leukemia (CLL).(Grzybowska-Izydorczyk et al., 2010)
In acute myeloid leukemia (AML), levels of Survivin expression were found to be
significantly predictive of shorter overall and event-free survival.(Carter et al., 2012) In
addition, the highest Survivin expression levels are detected in the CD34(+)CD38(-)
AML stem/progenitor cell populations,(Carter et al., 2012) further validating Survivin’s
potential as a prognostic biomarker and therapeutic target. Overexpression of Survivin in
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CD34+ hematopoietic cells has been found to induce hematological malignancies in vivo,
suggesting that it has a role in the development of these diseases.(Small et al., 2010)
Localization of Survivin to the nucleus versus cytoplasm is very important
because the functional dynamics of Survivin are dependent on the site of Survivin
expression.(Kumar et al., 2012) Using chemotherapeutic drugs in hematologic cancer,
Bernardo et al., reported that cytoplasmic Survivin was more relevant to the apoptotic
index than that associated with nuclear Survivin.(Bernardo et al., 2012) Investigating
Survivin’s cellular locations, alternative splice variant profiles within the context of
cancer health disparities and novel therapeutic modalities will continue to be important
areas of study.

Liquid Biopsy
The tumor microenvironment is being increasingly recognized as providing many
key factors necessary for many of the stages of disease progression including local
resistance, immune escape, and distant metastasis. Understanding this tumor
microenvironment, including the cells involved and the communications ongoing
between them will continue to prove instrumental in our understanding of cancer and
eventually our ability to control it if not terminate it. In order to fully “learn the
language”, there is a need for new biomarker discovery. Specifically, biomarkers that are
easily isolated and identified from blood, urine, saliva, cerebral spinal fluid, ascites, etc.,
as well as from tissue biopsies, will need to be identified. The term “liquid biopsy” has
been used recently to describe the source of these biomarkers and could be defined as
broadly as circulating tumor cells, circulating tumor DNA, exosomes and
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secretomes.(Rolfo et al., 2014) Differential expression of exosomal Survivin may serve
as a diagnostic and or prognostic marker, in early cancer patients and may soon lead to
the development of potential therapeutics for the treatment of these diseases.

Conclusions
Most efforts on the identification of candidate cancer biomarkers, and on
analyzing differences in the cancer biology that exists between African Americans and
Caucasian patients have focused on gene expression differentials in tumor tissues,
epigenetic issues such as methylation patterns and on single nucleotide polymorphisms
(SNPs). While these efforts have been necessary in providing important clues for
understanding biochemical mechanisms associated with cancer health disparities, it is
also imperative to develop non-invasive approaches that analyze indirectly and early in
the disease process, the molecular profiles of tumors. One recent study has investigated
the -31G>C promoter polymorphism across approximately 7,500 cancer cases and 9,000
controls.(Qin et al., 2014) This polymorphism was significantly associated with an
increased cancer risk in colorectal, gastric, and urothelial cancers. In contrast, this SNP
was remarkably decreased in patients with hepatocellular carcinoma. With regard to
ethnic diversity, this SNP was shown to increase cancer risk in Asian populations(Qin et
al., 2014) as well as a higher Wilms’ tumor risk in Serbian children.(Radojevic-Skodric
et al., 2012) Findings such as these encourage us to not only look at the overall
abundance of gene or protein products in racial disparities and cancer but to look deeper
into the minutia that may have been historically overlooked and may provide important
insights not before recognized as factors in cancer development and resistance.
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Recent studies have shown that small membrane-bound vesicles called exosomes
constitute the latest mode of intercellular information transfer or communication. This
exchange of molecular information is facilitated by their unique composition, which is
enriched with enzymes, structural proteins, adhesion molecules, lipid rafts, microRNA
and RNA. Importantly, cancer cells have been shown to secrete more exosomes than do
their normal counterparts indicating that exosomes can be used as diagnostic markers and
their active secretion has functional implications. In addition, recent studies revealed that
genes involved in inflammation and autoimmune responses are differentially up regulated
in cancer patients compared to controls. This could imply that differences in antitumor
immune responses may exist between racial groups in tumors.
It is very important to specifically target Survivin in a defined location for
therapeutic purposes. Survivin is a unique inhibitor of apoptosis with triple functionality:
in cell cycle regulation when it is present in the nucleus, inhibition of apoptosis when it is
in the mitochondria, and resistance to chemotherapy when it exists in the tumor
microenvironment packaged in exosomes. Survivin’s up regulation in specific cancers,
in addition to its presence in serum exosomes, make it an important molecule both as a
diagnostic as well as prognostic marker. Unfortunately, controversy exists as to whether
Survivin expression is favorable or unfavorable in the outcome of cancer. Survivin
expression is an unfavorable prognostic indicator in esophageal, hepatocellular, and
ovarian cancers, cholangiocarcinoma, and endometrial cancers but has associated
favorable outcomes in gastric, bladder, breast, ependymoma osteosarcoma and pancreatic
ductal adenocarcinomas.(Li et al., 2005, Carter et al., 2012) To validate its role, a large
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number of case-control studies need to be adapted. Subsequent studies exploiting the
exosomal packaging of Survivin may also one day be used in cancer therapeutics.
In conclusion, this review addresses an urgent need in the fight against cancer
health disparities: the need to identify and evaluate novel serum biomarkers such as
Survivin and its alternative splice variants for non-invasive early detection of cancer in
interventions that can be tailored to Americans of different ethnicities, ultimately, paving
the way for future studies focused on analyzing these biomarkers in larger cohorts of
ethnically diverse cancer patients.
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Abstract
Background: Survivin is expressed in prostate cancer (PCa), and its downregulation
sensitizes PCa cells to chemotherapeutic agents in vitro and in vivo. Small membranebound vesicles called exosomes, secreted from the endosomal membrane compartment,
contain RNA and protein that they readily transport via exosome internalization into
recipient cells. Recent progress has shown that tumor-derived exosomes play multiple
roles in tumor growth and metastasis and may produce these functions via immune
escape, tumor invasion and angiogenesis. Furthermore, exosome analysis may provide
novel biomarkers to diagnose or monitor PCa treatment.
Methods: Exosomes were purified from the plasma and serum from 39 PCa patients, 20
BPH patients, 8 prostate cancer recurent and 16 healthy controls using ultracentrifugation
and their quantities and qualities were quantified and visualized from both the plasma and
the purified exosomes using ELISA and Western blotting, respectively.
Results: Survivin was significantly increased in the tumor-derived samples, compared to
those from BPH and controls with virtually no difference in the quantity of Survivin
detected in exosomes collected from newly diagnosed patients exhibiting low (six) or
high (nine) Gleason scores. Exosome Survivin levels were also higher in patients that
had relapsed on chemotherapy compared to controls.
Conclusions: These studies demonstrate that Survivin exists in plasma exosomes from
both normal, BPH and PCa subjects. The relative amounts of exosomal Survivin in PCa
plasma was significantly higher than in those with pre-inflammatory BPH and control
plasma. This differential expression of exosomal Survivin was seen with both newly
diagnosed and advanced PCa subjects with high or low-grade cancers. Analysis of
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plasma exosomal Survivin levels may offer a convenient tool for diagnosing or
monitoring PCa and may, as it is elevated in low as well as high Gleason scored samples,
be used for early detection.

Key Words: biomarker, resistance, early detection, prostate, Survivin
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Introduction
Worldwide, prostate cancer (PCa) is the second most frequently diagnosed cancer
and the sixth leading cause of cancer death in males (Jemal et al., 2010, Jemal et al.,
2011). Increasing age, ethnicity and family history are the only established risk factors
and there are no known preventable risk factors established to date (Jemal et al., 2011).
Prostate cancers (PCa) are generally slow-growing malignancies that are characterized by
an imbalance in the rates of cell division and cell death (Lu S et al., 1999). Surgery and
radiation therapy are effective for localized disease but there is no effective treatment
strategy for recurrent or metastatic PCa that has failed surgery, radiation or hormonal
therapy (Klein EA & Kupelian PA, 2003). An important challenge to develop treatments
that are more effective depends upon our understanding of the molecular mechanism(s)
of PCa progression, which will lead us to identify many potential therapeutic target genes
and processes that are involved in apoptosis, cell proliferation, metastasis, and growth
factor signaling. Total prostate-specific antigen (PSA) has revolutionized PCa screening
and has resulted in an overall decrease in PCa metastasis and death (Shariat et al., 2011).
Unfortunately, the application of PSA screening has also led to over-detection and
overtreatment as PSA is neither cancer specific nor a surrogate for the biologic behavior
of PCa (Han et al., 2003, Shariat et al., 2011). Elevations in PSA levels can reflect a
cancer presence but can also be present as a result of infection, chronic inflammation or
benign prostatic hyperplasia (BPH) (Freedland et al., 2005, Bjartell et al., 2011). BPH
has been shown to exist in greater than 70% of men over the age of 70 but is not
considered to be a precursor of prostate cancer though they frequently coexist (Chang et
al., 2012). It is therefore necessary to continue to screen for biomarkers that are cancer-
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specific and that are detectable early in the course of the disease.
The processes of both cell survival and cell death have involved highly regulated
signaling pathways that are currently the subject of intense investigation. It is known that
regulation of apoptosis has a central role in the development of prostate cancer and its
progression to an androgen-independent state, which is due, in part to up regulation of
antiapoptotic genes after androgen deprivation (Li Y et al., 2004, Zhang M et al., 2005,
Guo Z et al., 2006). Several lines of evidence suggest that one of the main events
associated with progression after therapeutic failure is increased resistance to apoptosis
(Denmeade SR, 1996, Howell SB, 2000), mainly due to the up regulation of antiapoptotic
genes, including Bcl-2, Bcl-XL, Mcl-1 (Krajewska M et al., 1996), and Survivin (Altieri
DC, 2003b). Survivin, an inhibitor-of-apoptosis (IAP) protein family member, is
associated with PCa development, progression, and drug resistance (Krajewska M et al.,
2003, Kishi H et al., 2004, Shariat SF et al., 2004, Koike H et al., 2008). Recent
evidence indicates that the overexpression of Survivin in PCa tumors is associated with
poor prognosis and increased tumor recurrence (Nakahara T et al., 2007). In contrast, it
has also been shown that knockdown of survivin expression by siRNAs enhances the
chemosensitivity of prostate cancer cells, reducing tumorigenicity (Shen et al., 2009).
Traditionally, Survivin has been viewed as a cytoplasmic or nuclear protein.
Recently, Survivin has been also shown to exist extracellularly, contained in small
membrane bound vesicles known as exosomes (Khan S et al., 2009, Khan S et al., 2011).
Exosomes are present in serum and urine and contain a wide range of proteins and RNAs
and represent their tissue of origin making them a possible source or pool of novel PCa
biomarkers (Duijvesz et al., 2011). Consistent with Survivin’s association with
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unfavorable clinicopathological parameters, extracellular trafficking of Survivin
throughout the tumor microenvironment could be responsible for augmenting the
aggressive status of a tumor while prohibiting or minimizing therapeutic results. We
have recently shown that exosome-bound Survivin protein can be secreted by cancer cells
and be taken up by surrounding cells, producing a field effect that confers a general
stress-survival phenotype .
Our present study was designed to investigate the existence of exosomal Survivin
in the plasma of PCa patients with a variety of PCa presentations and to compare its
exosomal expression levels to those found in control volunteers with no diagnosis of
cancer and to patients diagnosed with benign prostatic hyperplasia or BPH. For the past
25 years the Gleason grading system has been used to help evaluate the prognosis of men
with prostate cancer. Together with other parameters, prostate cancer has been staged as
a means to predict prognosis and guide therapy (Fine & Epstein, 2008). Extracellular
Survivin was found highly expressed in the plasma exosomes of PCa patients exhibiting
Gleason scores of 6 (low) and 9 (high), and in patients who had relapsed on
chemotherapy. However, there were no significant differences in Survivin levels
between subjects with low or high Gleason scores. In addition, though exosomes
containing Survivin were found in the serum from patients with a diagnosis of BPH, the
overall level was significantly lower than that found in the plasma from PCa patients.
We believe that in addition to diagnostic markers, prognostic, predictive and therapeutic
markers are needed to act as surrogate endpoints in forecasting disease severity, choosing
treatments, and monitoring responses to therapies (Mikolajczyk et al., 2004, Fradet,
2009, Fiorentino et al., 2010, Ploussard & de la Taille, 2010). Our demonstration of
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exosomal Survivin in the plasma of patient with newly diagnosed low-grade PCa
provides a rationale for studies to investigate the utility of exosomal Survivin as an early,
easily measured biomarker for PCa diagnosis. Exosomal Survivin may also be studied as
a biomarker to monitor treatment of subjects with advanced PCa.

Results
Plasma Levels of Survivin in Healthy Controls and PCa Patients
Survivin was detectable in the plasma from all healthy control subjects and PCa
patients. The measurement results of plasma Survivin in normal healthy controls and
PCa patients are shown in Figure 1A. The mean plasma Survivin levels were
significantly different between the healthy control subjects (61.5 pg/ml in controls
[n=10]) and the different cancer patient groups (Gleason 6 = 401.7 pg/ml [n=10], Gleason
9 = 375.2 pg/ml [n=10], and subjects resistant to the the chemotherapy agent Taxotere =
410 pg/ml [n=8]; P< 0.05 for each comparison vs. control). When the Survivin levels
were compared among the three groups of PCa patients in two-way comparisons, none
were significantly different from the others.

Survivin Can Be Collected From Serum Taken From Healthy Controls, BPH and PCa
Patients
Like what has been measured above in plasma, Survivin was also detectable in the
serum from patients having no prior diagnosis of cancer as well as in patients having the
diagnosis of benign prostatic hyperplasia (BPH) and those diagnosed with prostate cancer
(PCa) (Figure 1B). The mean serum Survivin levels were significantly (P<0.001) higher
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Figure 1. Quantification of Survivin levels in PCa plasma (A) and serum (B) samples by
ELISA. A. Survivin levels were measured in plasma derived from Gleason 6 (n=10),
Gleason 9 (n=10), and Taxotere-resistant subjects (n=8). B. Survivin levels were measured
in serum derived from BPH (n=20), and PCa (n=19). Comparisons were accomplished
using MANOVA with normal healthy controls (n=10 and 6 respectively). (**, p<0.05, ***,
p<0.001; statistically significant).
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in the PCa subjects (150 pg/ml [n=19]) than in the serum processed from normal controls
(59.7 pg/ml [n=6]) and from BPH patients (55 pg/ml [n=21]).

Plasma and Serum Survivin in PCa Patients Exists in an Exosomal Pool
We have previously demonstrated that cultured PCa cells release Survivin into the
extracellular milieu within exosomes (Khan S et al., 2009). These small, membranevesicles are also known to occur in the plasma as well as serum of cancer patients
(Mitchell et al., 2009, Koumangoye et al., 2011). Exosomes were therefore collected by
differential centrifugation, and quantitated using the acetylcholinesterase enzymatic
assays as we and others have previously described (Johnstone, 2006, Khan S et al.,
2011). The mean plasma exosome levels were significantly different between the healthy
control subjects and the different cancer patients groups (P< 0.001) whereas significant
differences in exosome quantity were not found among the PCa patient sample groups
(Figure 2A). This was also the case when comparing the exosome quantities found in
BPH and PCa samples to that of the healthy control subjects (Figure 2B). Interestingly,
there appears to be a measureable difference in Survivin and in exosomes depending
upon the source as both Survivin and exosome quantities were higher when purified from
plasma then when purified from serum.

Plasma-Derived Exosomes Contain Survivin
Exosomes were characterized by immunoblotting for the amount of Survivin
protein and Lysosomal-associated membrane protein 1 (LAMP1). LAMP1 is a known
exosome protein which is commonly used to ensure proper Western blot loading (Quah
& O'Neill, 2005, Bhatnagar et al., 2007, Khan S et al., 2011). Exosomes isolated from
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Figure 2. Exosomal contents in PCa patients plasma (A) and serum (B) samples by using
the acetylcholinesterase activity assay. A. Exosome levels were measured in plasma
derived from Gleason 6 (n=10), Gleason 9 (n=10), and Taxotere-resistant subjects (n=8).
B. Exosome levels were measured in serum derived from BPH (n=20), and PCa (n=19).
Comparisons were accomplished using MANOVA with normal healthy controls (n=10 and
6 respectively). (**, p<0.05, ***, p<0.001; statistically significant).
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PCa patient plasma exhibited enhanced Survivin loads compared to exosomes isolated
from controls (Figure 3). Western blot analysis showed that little exosomal Survivin was
detectable in plasma samples collected from six controls having no previous diagnosis of
cancer in comparison to the exosome-specific protein Lamp1 (Figure 3A). In contrast,
exosomes isolated from all twenty pre-treatment PCa subjects contained high amounts of
Survivin protein compared to LAMP1 protein levels (Figure 3B). Interestingly, there
was no significant difference in exosomal Survivin content between patients with
Gleason 6 PCa and those with Gleason 9 PCa (Figure 3C) when normalized against
Lamp1 (p<0.05).

Differential Expression of Survivin Exists in BPH and PCa-Derived Exosomes
As above, exosomes collected from BPH and PCa patient serums were
characterized by immunoblotting for Survivin and LAMP1 protein (Figure 4A).
Exosomes isolated from PCa and BPH patient serums exhibited enhanced Survivin loads
compared to exosomes isolated from controls (Figure 4A, Figure 4B and Figure S1).
Interestingly, though Survivin was detected in most and elevated in certain BPH patients,
its overall level was significantly less than that found in PCa and there was no significant
difference measured between BPH and control patient serums (Figure 4B).

PCa Patients with Disease Progression Express High Levels of Exosomal Survivin
Lastly, we evaluated exosomes collected from PCa patients who experienced
disease progression while on treatment with chemotherapy. Like in our Gleason patient
exosomes, Western blotting showed Survivin protein levels (Figure 5A) were markedly
higher when compared to cancer-free control subjects, which was confirmed to be

47

Figure 3. Western Blot Analysis of exosomal Survivin in untreated PCa plasmas. A.
Antibodies for Survivin and Lamp1 were used for Western blotting of control patientpurified exosomal protein. B. Both Survivin and Lamp1 antibodies were detected in the
Western Blotting of exosomes-derived from Gleason 6 and Gleason 9. C. Proportion
analysis of Survivin density to Lamp1 density were shown in both Gleason 6, and Gleason
9 with normal healthy controls (**, p<0.05, statistically significant) with no significance
recorded between Gleason 6 and Gleason 9 plasma-derived exosomes.
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Figure 4. Western Blot Analysis of exosomal Survivin in normal control, BPH and
untreated PCa serum samples. A. Antibodies for Survivin and Lamp1 were used for
Western blotting of patient-purified exosomal protein. B. Proportion analysis of Survivin
density to Lamp1 density were shown in both BPH and PCa with normal healthy controls
(**, p<0.05, ***, p<0.001; statistically significant) with no significance recorded between
normal controls and BPH.
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Figure 5. Western Blot Analysis of exosomal Survivin and Lamp1 in Taxotere-resistant
PCa patients. A. Survivin and Lamp1 antibodies were shown positive. B. Densitometric
analysis of Survivin/Lamp1 expression in a healthy control (normal) and chemoresistance
(CR) cases (**, p<0.05, statistically significant).
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Figure S1. Western Blot Analysis of exosomal Survivin in normal control, BPH and
untreated PCa serum samples. Antibodies for Survivin and Lamp1 were used for Western
blotting of patient-purified exosomal protein.
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significant after densitometric analysis (Figure 5B).

Clinical and Pathological Characteristics
Pretreatment data regarding initial plasma Survivin and PSA levels and Gleason
scores were acquired for the patients studied. These pathological characteristics are
detailed in Tables 1-4. In all, eight cases of prostate cancer recurrence after conventional
treatment, ten cases of Gleason 6, ten cases of Gleason 9, (Table 1); and ten control
cases (Table 2) were collected with plasmas analyzed. PSA from the plasma (clinical
report) and from the ultracentrifuge-purified exosomes showed that though the protein
concentrations were not identical, there was similarity in the trend of plasma to plasmaderived exosome PSA values. Importantly, Survivin amounts though significantly less in
the exosomes were more consistent across the patients evaluated, and given the
sensitivity of the ELISA, picograms for Survivin compared to nanograms for the PSA, is
more accurate.
Further studies using sera instead of plasma were performed on six controls, twenty
BPH cases (Table 3) and 19 additional PCa cases (Table 4). Like before, ELISA results
from Survivin provided a more sensitive and stable quantitation than did the ELISA for
PSA. Quantitation from the sera of BPH patients showed an average of 52.9 pg/ml
Survivin and 1.3 ng/ml PSA. In comparison, when evaluated from PCa patients, Survivin
averaged 149 pg/ml and PSA averaged 0.3 ng/ml (Tables 3 and 4). BPH numbers for
both Survivin and PSA are nearly 3 fold lower than in the PCa patient sera.
Unfortunately, purchased BPH samples did not come with the clinical PSA ELISA
quantities that we have from the PCa cases (Table 3).
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Correlations of Survivin with PSA
Of the patient’s plasma/serum samples evaluated for Survivin, all samples
(Gleason 6, Gleason 9, recurrence, or PCa samples) exhibited greater than 100 pg/mL
Survivin (Table 5). In contrast, only 60% of Gleason 6, 80% of Gleason 9 plasmas and
84% of PCa sera had a PSA of greater than 4 ng/mL. Recurrent patient plasmas all had
greater than 4 ng/mL. In control plasmas and BPH sera, no sample had a Survivin
concentration greater than 100 pg/mL and no PSA concentration greater than 4 ng/mL
(Table 5).

Discussion
Prostate carcinoma resists apoptosis with altered expression of both pro- and on
Survivin, a multifunctional member of the inhibitor of apoptosis (IAP) gene family that
counteracts cell death and controls mitotic progression. Selective overexpression of
Survivin has been associated with higher tumor grade, advanced disease stage, rapid
tumor progression, short patient survival, and resistance to therapy in patients with
various malignancies (Krajewska M et al., 2003, Kishi H et al., 2004, Koike H et al.,
2008).
Survivin exists in a number of subcellular locations such as the mitochondria,
cytoplasm, and nucleus. Recently it has also been found in the extracellular space (Khan
S et al., 2009, Khan S et al., 2011). We have shown that extracellular Survivin exists in
multimolecular complexes which include heat shock proteins (Khan S et al., 2011).
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Table 1. Survivin ELISA and PSA levels of plasma from Chemo-resistance, Gleason
6, and Gleason 9 patients are shown.

Patients
ID#
006
009
010
012
013
002a
002b
007

Figure
ID#
CR1
CR2
CR3
CR4
CR5
N/A
N/A
N/A

028
044
061
066
077
085
089
093
101
117

1
2
3
4
5
6
7
8
9
10

270
1
367
2
381
3
396
4
401
5
410
6
440
7
456
8
474
9
517
10
N/A: Not available

Chemo-Resistance
Survivin
PSA*
ELISA(pg/mL)
(ng/mL)
503+/-81.9
110
382+/-29.1
51.5
435+/-32.4
15.8
305+/-19.9
55.4
413+/-141.5
970
258+/-5.2
235
246.6+/-183
8.9
327+/-10.8
62.9
Gleason 6
332+/-15.3
3
328+/-54
2.4
330+/-34
5.8
332+/-4.5
8.1
313+/-26.8
4.4
1366.5+/-82.7
4
311+/-7.5
2.9
306+/-25.4
4.1
317+/-30.6
3.1
311+/-22.9
7
Gleason 9
386+/-27.6
11
336+/-15.8
6.7
393+/-48.1
4.2
348+/-13.7
3.1
287+/-9.1
4.7
603+/-19.6
9.3
301+/-19.9
9.3
306+/-18.2
5.54
417+/-121.7
3.65.1
375+/-7.9
17.8
*Clinical PSA values
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Exosomal PSA (ng/mL)
62.28+/-1.2
38.13+/-1.5
4.37+/-7
304.85+/-76.9
443.25+/79.84+/-11.7
1.32+/-0.4
31.91+/-6.6
2.43+/-0
2.90+/-0.2
0+/-1.1
6.10+/-0.5
5.63+/-0.7
1.30+/-0.3
4.08+/-0.9
0.39+/-0
0.93+/-0
0+/-0.7
0.21+/-0.1
0.42+/-3.4
0+/-0.9
2.67+/-0
4.33+/-18
2.14+/-0
2.08+/-0.3
0.61+/-0.3
0.36+/-0.2
0+/-1.4

Table 2. Survivin ELISA and PSA levels of plasma from controls
with no diagnosis of cancer.
Patients
ID#
OPN 118
OPN 119
OPN 120
OPN 121
OPN 122
OPN 123
OPN 124
OPN 125
OPN 126
OPN 127

Figure ID#
N1
N2
N3
N4
N5
N6
N7
N8
N9
N10

Survivin (pg/mL)
67.5+/-0
65+/-14.9
75+/-7
60+/-7
45.75+/-1.4
60+/-7.1
67.5+/-0
71.6+/-10
35+/-14
67.5+/-0

Exosome PSA (ng/mL)
0+/-0
0+/-0.2
0+/-0.3
0+/-0.2
0+/-1.0
0+/-1.5
0+/-.5
0+/-1.5
0+/-.5
2.17+/-0.4
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Table 3. Survivin ELISA and PSA levels of Sera from BPH patients are shown.
Patients ID#

Figure ID#

VCT08
G918
4PHH
OSWG3
XHZN
87LUH
CC51Y
XHWCG
IOAYY
ZUQ1B
L8K8F
WBZVY
X3GDZ
9UXFW
JCO8M
XWKEL
H2GY6
PPAQH
AU4AD
DXCOB

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Survivin
ELISA(pg/mL)
44.5+/-4.94
46.5+/-0.7
45+/-5.6
46+/-7
64.5+/-6.36
25+/-35.3
24.5+/-34.64
45.5+/-0.7
49.5+/-0.7
76.5+/-21.2
54.5+/-2.12
52.5+/-7.7
49+/-1.14
89+/-2.8
55.5+/-2.12
53+/-11.3
45.5+/-4.9
54.5+/-12
66.5+/-3.5
70.5+/-0.7
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Exosomal PSA
(ng/mL)
0.955+/0
1.955
2.17
0
2.67
2.305
1.88
0
2.275
2.745
2.5
1.955
0
2.35
0
2.035
0
0
0

Table 4. Survivin ELISA and PSA levels of Sera from Prostate Cancer patients.
Patients
Figure ID#
ID#
642
1
6227
2
6636
3
3918
4
3960
5
2060
6
304
7
624
8
286
9
2828
10
14739
11
13077
12
6129
13
9508
14
14824
15
13406
16
9594
17
5117
18
69
19
*Clinical PSA Values

Survivin
ELISA(pg/mL)
140.1+/-0.34
147.13+/-4.4
154.21+/-7.24
142.93+/-1.88
140+/-0.03
139+/-1.25
133.13+/-7
123.4+/-7.39
157.16+/-2.44
155.75+/-5.7
154.58+/-2.71
155.7+/-2.1
183+/-19.79
179+/-26.87
135.5+/-7
146+/-2.82
145+/-2.12
149+/-7
146+/-5.6
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PSA
(ng/mL)
6.2
3.29
4.5
5.2
13.5
10.6
5.3
8.8
2.73
3.9
6.82
7.1
5.4
9.4
7
8.8
6.56
42
58

Exosomal PSA
(ng/mL)
0
0
0
0
0
0
0
0
0
0
0
1.73
0
1.835
0
2.335
0
0
0

Table 5. Correlation of Survivin and PSA levels from Plasma.
Patients
Normal
Gleason 6
Gleason 9
Recurrences
BPH
PCA

Survivin
(pg/mL)
<100 (n=10) (100%)
>100 (n=0) (0%)
<100 (n=0) (0%)
>100 (n=10) (100%)
<100 (n=0) (0%)
>100 (n=10) (100%)
<100 (n=0) (0%)
>100 (n=8) (100%)
<100 (n=20) (100%)
>100 (n=0) (0%)
<100 (n=0) (0%)
>100 (n=19) (100%)
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PSA
(ng/mL)
<4 (n=10) (100%)
>4 (n=0) (0%)
<4 (n=4) (40%)
>4 (n=6) (60%)
<4 (n=2) (20%)
>4 (n=8) (80%)
<4 (n=0) (0%)
>4 (n=10) (100%)
<4 (n=20) (100%)
>4 (n=0) (0%)
<4 (n=3) (16%)
>4 (n=16) (84%)

Furthermore, we have also shown that these complexes reside in or on exosomes, and that
cancer treatment can enhance release of such exosomes from cancer cells (Khan S et al.,
2011). Extracellular Survivin is able to mediate a pro-survival field effect through its
secretion by cancer cells and uptake by surrounding normal and transformed cells (Khan
S et al., 2009). Linking extracellular Survivin’s ability to enhance cellular proliferation,
survival and tumor cell invasion with a membrane-protective trafficking modality
provides additional support for the hypothesis that Survivin plays a pivotal role in the
pathobiology of cancer cell growth and protection from therapeutic interventions.
Several previous studies have examined the plasma levels of Survivin in cancer
patients (Sugahara et al., 2004, El-Attar et al., 2010). In adult T-cell leukemia and the
supernatants from in vitro cultures of solid-tumor cells, the levels of Survivin protein was
low compared to the cellular Survivin protein and mRNA levels (Sugahara et al., 2004).
This finding resulted in the conclusion that Survivin protein levels in plasma do not
reflect cellular Survivin levels. Furthermore, Survivin plasma levels were evaluated
compared to alpha fetoprotein (AFP) in patients with chronic hepatitis C viral infection
(HCV) with and without hepatocellular carcinoma (HCC) (El-Attar et al., 2010). Though
not concluded to be as reliable in these studies as AFP, Survivin levels were determined
to be measurable and significant in patients suffering with HCV and measurable but not
significant in those with HCC. Though not entirely clear, these results could be
explained by the finding that HCV-infected HCC cells became more resistant to cell
death and thus Survivin release compared to control or HCV-infected cells alone (ElAttar et al., 2010).
The prostate specific antigen (PSA) assay has been controversially utilized in
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prostate cancer screening though initially it was envisioned as a tool for evaluating
treatment response (Croswell et al., 2011). Its use as a screening tool was driven by both
the US prostate cancer burden and a need to detect its presence at a time that would allow
for curative treatment to begin. Unfortunately, its use is believed to have led to both over
diagnosis and overtreatment and hence the urgent need for novel biomarkers to be found
to supplement PSA for management and treatment (Mazzola et al., 2011). Exosomal
Survivin measurements may provide another plasma-based assay for the presence of PCa.
In the present study, we have identified for the first time that exosomes containing
Survivin can be purified from plasma collected from patients with a diagnosis of PCa.
Although there was little difference in exosome quantity, exosomal Survivin levels were
higher in exosomes purified from PCa patients than from the sera of normal controls. In
addition, in this study and that performed by others (Sugahara et al., 2004, El-Attar et al.,
2010), plasma-quantitated Survivin in samples taken from patients with no confirmed
cancer diagnosis, also had reduced Survivin levels compared to PCa patient sera. The
source of this exosomal Survivin pool, though unclear, may originate in immune cells
(Iero et al., 2008) such as lymphocytes (Clayton et al., 2005), monocytes (Valenti et al.,
2007) and dendritic cells (Quah & O'Neill, 2005), all Survivin containing cells (Fukuda
& Pelus, 2006) which have been shown to release exosomes. Survivin expression is
associated with established features of biologically aggressive prostate carcinoma, such
as higher final Gleason score and metastasis to regional lymph nodes (Shariat SF et al.,
2004). In our study we found that patients who had failed treatment with Taxotere had
elevated levels of exosomal Survivin. In addition, and of special interest, we found that
patients presenting with either mid (Gleason 6) or high (Gleason 9) Gleason scores
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exhibited higher exosomal Survivin levels with no significant difference in Survivin
content between them. Our findings, though more robust in the plasma we studied appear
in agreement with what has been found with urine, tumor exosomes and PSA (Mitchell et
al., 2009). In these studies, urine exosome PSA is described as present in 20 of 24 PCa
specimens while in our hands, tumor exosome Survivin is found in 47 of 47 specimens.
Whether or not cancer treatment will affect tumor exosome Survivin levels has yet to be
evaluated.
In this current study, we provide compelling evidence that circulating Survivin
may be a useful diagnostic and prognostic marker for human PCa. Our results indicate
that Survivin, analyzed directly from serum/plasma or from serum/plasma-derived
exosomes, was lower in patients with BPH and healthy controls than in men with PCa.
Survivin levels did not change, being consistently high, with regard to Gleason score and
patients having recurrence, suggesting that Survivin levels could be used for early
detection and could perhaps one day more accurately differentiate BPH from PCa.
Comparing patients with and without tumors, but both having high PSA values will also
be an important next step, as in our hands all the BPH samples we have acquired have
relatively non-cancer PSA values (Williams & Naz, 2010).
The role of exosomal Survivin is still unknown. It is possible that a therapystressed, cellular release of exosomes containing Survivin and other antiapoptotic
proteins, RNAs or miRNAs is performed as a final attempt to protect themselves from the
stress that exists within the tumor microenvironment. Larger studies with more events
and longer follow-up will be required to develop a more definitive statement regarding
the association of Survivin expression in exosomes or in the tumor microenvironment
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with prostate carcinoma progression and as importantly, metastasis and survival. These
findings will provide a rationale for further evaluation of exosomal Survivin and its role
in resistance to androgen-based therapy in prostate carcinoma and raise the possibility of
targeted combination therapy for advanced prostate cancer.
Our finding that Survivin, a unique human inhibitor of apoptosis (IAP), has
intercellular transport and signaling capabilities is significant. Consistent with Survivin’s
association with unfavorable clinicopathological parameters, trafficking Survivin
throughout the tumor microenvironment can drive the aggressive status of the tumor,
prohibiting or minimizing therapeutic results. In our current work we show that though
the overall number of exosomes being shed into patient plasma does not significantly
change during the development of cancer, the level of Survivin in those exosomes
increases significantly. Importantly, progression from mid- to late-stage does not drive
an appreciable Survivin increase indicating that Survivin may prove useful as a
biomarker for earlier detection of prostate cancer. Indeed, Survivin-based testing,
performed on tumor-exosomes, will allow molecular-based diagnosis that in time may
also aid in therapy decisions and disease response surveillance leading to better
management of prostate cancer.

Materials and Methods
Patient Plasma and Serum
Plasma samples were collected from ten healthy male volunteers, and twentyeight PCa patients. Plasma from twenty PCa subjects was obtained from the specimen
bank of the SPECS consortium which is an observational clinical trial which utilizes
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prostate tissue and clinical values obtained by informed consent to derive gene signatures
predictive of outcome at the time of diagnosis. SPECS is directed by Dr. Dan Mercola
from the University of California, Irvine. Samples were pre-prostatectomy plasma
randomly selected from ten low-grade PCa cases (Gleason 6) and ten high-grade PCa
cases (Gleason 9). In addition, plasma from eight advanced-disease PCa patients
participating in a second-line chemotherapy trial was also collected. These patients had
failed chemotherapy with Taxotere. Nineteen serum samples were collected from PCa
patients and six controls through the San Manuel Band of Mission Indians Biospecimen
Laboratory at Loma Linda Universities Cancer Center. Twenty BPH samples were
purchased from Bioserve Biotechnologies, Beltsville, MD. Bioserve Biotechnologies as
provider of these samples is covered as defined in the HIPPA Act of 1996 as is providing
them to us with a limited data set of protected health information.
Blood was collected in vacuum tubes containing sodium heparin. The tubes were
centrifuged at 2000g x 7 minutes, and the plasma was then removed and aliquoted for
storage at -80 C. All samples were obtained in the course of IRB-approved studies,
following the documentation of informed consent in accordance with university policy at
both Loma Linda University and the University of California at Irvine.

Human Survivin Immunoassay
Whole plasma samples were subjected to a commercially available human
Survivin Immunoassay (R&D systems, Minneapolis, MN) using the manufacturer’s
instructions in order to quantitate Survivin concentrations.
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Exosome Isolation
Plasma microvesicles were isolated as previously described, with minor
modifications (Caby MP et al., 2005). Thawed, cryopreserved plasma (2 ml) was
centrifuged for 30 min at 500 x g, 45 min at 12,000 x g and 18 h at 110,000 x g. Pellets
were resuspended in a large volume of PBS, filtered through a 0.22-μm filter (Millipore,
Billerica, MA) and centrifuged at 110,000 x g for 1 h. Microvesicle pellets were washed
once in a large volume of PBS, centrifuged at 110,000 x g for 1 h and re-suspended in
50–200 ml of PBS. The amount of 110,000 x g pellet proteins recovered was measured
using the BCA protein assay kit (Pierce, Rockford, IL). Exosomes were used as fresh
preparations for immunoblotting or were conserved at -80

C for later use. For serum

samples, the commercially available ExoQuick (SBI, Mountain View, CA) was
employed as described by the vendor. Briefly, 100 μL of serum was incubated with 100
L of ExoQuick solution followed by a 2 hr incubation at 4 °C followed by
centrifugation at 1500 x g for 30 minutes. After centrifugation the exosomes appear as a
beige or white pellet at the bottom of the vessel which is then reconstituted with 500 μL
of dH2O.

Exosome Quantification
To quantify the amount of exosomes released, we assessed the activity of
acetylcholinesterase, an enzyme that is associated with these vesicles.
Acetylcholinesterase activity was assessed as described by Savina et al. (Savina A et al.,
2003). Briefly, 40 μl of the exosome fraction was suspended in 110 μl of PBS. 37.5 ml
of this PBS-diluted exosome fraction was then added to individual wells on a 96-well
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flat-bottomed microplate. 1.25 mM acetylthiocholine and 0.1 mM 5,50-dithiobis(2nitrobenzoic acid) were then added to exosome fractions in a final volume of 300 μl, and
the change in absorbance at 412 nm was monitored every 5 min for 30 min.

Human PSA Immunoassay
Isolated exosomes from patients` plasma were subjected to human Prostate
Specific Antigen (PSA) using a PSA Immunoassay (American Research Products, Inc.,
Waltham, MA, USA) kit following the manufacturer’s instructions in order to quantitate
PSA concentrations in exosomes.

Western Blot Analysis
For Western blot analysis, cells or exosomal preparations were lysed using lysis
buffer (50 mM Tris (pH 7.5), 1% NP40, 0.25% DOC, 150 mM NaCl2, 1 mM PMSF, 10
μg/ml Aprotinin/ leupeptin/pepstatin, 20 mM NaF, 0.2 mM EGTA, 1 mM EDTA (pH
8.0), H2O). For protein concentrations the BCA assay (Pierce, Rockford, IL) was used.
Proteins from exosomes (20–40 μg) were separated using 12% Bis–Tris polyacrylamide
gels, transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA)
and probed using the following antibodies: mouse monoclonal anti-LAMP1 (Abcam,
Cambridge, MA), and rabbit polyclonal anti-Survivin (Novus, Littleton, CO). Secondary
antibodies (IR-Dye conjugated) were goat anti-rabbit and goat anti-mouse
immunoglobulin (LICOR, Lincoln, Nebraska). Immunoreactive bands were detected
using the Odyssey Imaging System (LICOR, Lincoln, Nebraska) and quantified using
ImageQuant software.
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Statistical Analysis
Multiple comparisons among different groups were calculated by using Multiple
Analysis of Variance (MANOVA). Student t-test (two-tailed) was used to evaluate the
significance of changes between control groups and experimental groups. Probability
values P<0.05 were considered statistically significant.
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Abstract
Prostate cancer (PCa) remains the most frequently diagnosed male malignancy in
Western countries and the second most common cause of male cancer death in the United
States. The relatively elevated PCa incidence and mortality among African American
men makes this cancer type a challenging health disparity disease. To increase the chance
for successful treatment, earlier detection and prediction of tumor aggressiveness will be
important and need to be resolved. This study demonstrates that small membrane-bound
vesicles shed from the tumor called exosomes contain ethnically and tumor-specific
biomarkers, and could be exploited for their diagnostic and therapeutic potential.
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Introduction
Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer in men
and the second leading cause of male cancer deaths in the United States, accounting for
233,000 new cases and 29,480 deaths in 2014 (Siegel et al., 2014). The incidence of the
disease has an uneven geographic distribution with the highest rates recorded in
Australia, North and Western Europe and the United States (Jemal et al., 2011). The
incidence and mortality of the disease is disproportionately high among African
American (AA) men compared to other ethnicities in the United States (Aizer et al.,
2014). An interesting note is that the disease incidence appears to be lower among Black
men in Africa, although this has been attributed to the lack of adequate and sufficient
statistics from this region of the world (Tindall et al., 2014).
While the basis for PCa health disparities is not well understood, evidence points
to the interplay between socioeconomic, environmental, and biologic/genetic factors
(Aizer et al., 2014). A number of risk factors for PCa have been examined in the
literature including chronic inflammation of the prostate (infectious and non-infectious),
hormonal factors (elevated testosterone, leptin etc.), smoking, dietary and genetic factors;
among others. Smith et al., described the link between the susceptibility gene HPC-1
(Hereditary PCa) and an increased risk of developing PCa, especially in younger patients
(Smith et al., 2011). Overall, PCa is believed to be a disease of multifactorial origin.
Prostate Specific Antigen (PSA) combined with a digital rectal exam has
remained the standard of screening for PCa for the past two to three decades. PSA was
first described as a marker for human semen in forensics but it was subsequently
demonstrated in the serum of men with prostate disease (Verma et al., 2014). The test
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was however intended for surveillance of diagnosed PCa patients. There was a sharp rise
in newly diagnosed cases in the early 1990’s attributed to the introduction of PSA as an
FDA-approved screening test for PCa. Coincident with this increase in the number of
new cases diagnosed was a pathologic migration toward a more favorable (early disease)
stage at diagnosis (Bryant & Lilja, 2014, Darwish-Yassine et al., 2014). Non-palpable
PCa (and therefore perhaps clinically treatable disease) now accounts for 70-80% of
newly diagnosed cases (Kardasevic & Delic-Redzepagic, 2014, Powell et al., 2014).
This may at least in part explain why the combined 5 and 10 year survival for all stages
of PCa is currently at 99% and 91% respectively. The true clinical value/advantage of
using serum PSA as a screening test has been recently called into question. While the use
of this test has increased the proportion of patients with lower tumor stage at the time of
diagnosis, its value is still debated because of its limitations. These limitations include
the cut-off PSA value of 4.0 ng/ml which fails to detect a significant number of prostate
tumors; PSA screening has not been demonstrated to improve health outcomes,
particularly in older men; PSA is not specific for PCa since its levels can be elevated in
patients with benign prostatic hyperplasia (BPH) and prostatitis, leading to a falsepositive finding of up to 60-80% of prostate biopsies; and obesity lowers PSA levels,
which in theory could lead to delayed detection of PCa and worse clinical outcome
(Bradley et al., 2013). Moreover, the lack of specificity of PSA as a screening tool has
also led to many possibly unnecessary diagnostic (biopsies) and therapeutic procedures.
The conclusions from the European Trial of PCa screening was that 1410
screenings/biopsies had to be performed and 48 additional cases treated in order to
prevent one death from PCa (Loeb et al., 2011). It should be noted, however, that most
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of the information available on the efficacy of the PSA test is based on studies of men of
European descent and that despite its limitations, PSA screening is still highly
recommended for AA men ages 45 and above (Faraday et al., 2009). The limitations of
the PSA test demand increasing the efforts to identify novel biomarkers that will
supplement this test and enhance early PCa detection, management and therapeutic
response. For this purpose we have initiated the evaluation of small membrane-bound
vesicles called exosomes derived from PCa patients from different ethnicities for the
possibility that they may contain yet undiscovered biomarkers. Potentially, these
biomarkers could be tailored for early PCa detection and management in AA men, with
the ultimate goal of reducing or eliminating PCa health disparities.
Recent studies have shown that tumor-derived exosomes are key modulators of
cell to cell and cell to extracellular communication within the tumor microenvironment
(Johnstone, 2006). Exosomes play an important part in this communication due to their
ability to transport cancer-promoting material such as protein, RNA and miRNA
(Johnstone, 2006, Khan S et al., 2011, Khan et al., 2015). In order to successfully treat
cancer, it will be crucial to develop therapeutic strategies that not only target tumor cells
but also the mediators within the tumor microenvironment that modulated many aspects
of the etiology of this disease (Aspe et al., 2014, Asuncion Valenzuela et al., 2015,
Valenzuela et al., 2015). However, enhanced treatment capabilities are the direct result of
earlier detection which will depend significantly on the early discovery of biomarkers
shed by these tumors (Properzi et al., 2013).
Exosomes are present in serum, plasma and urine and contain a wide range of
proteins and RNAs, representing their tissue of origin thus making them a possible source
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or pool of novel PCa biomarkers (Duijvesz et al., 2011). Our present study was designed
to profile the exosomal proteins from the plasma of ethnically diverse PCa patients and
control individuals with no diagnosis of PCa, and to compare these exosomal profiles
between the different ethnic groups. We believe that in addition to diagnostic markers,
prognostic, predictive and therapeutic markers are needed to act as surrogate endpoints in
forecasting disease severity, choosing appropriate treatment modalities, and monitoring
responses to therapies (Mikolajczyk et al., 2004, Fradet, 2009, Fiorentino et al., 2010,
Ploussard & de la Taille, 2010). Our previous demonstration of exosomal Survivin, an
inhibitor of apoptosis and indicator of cancer severity, in the plasma of patients with
newly diagnosed PCa (Khan et al., 2012) provided a rationale for studies to investigate
the utility of exosomal content as a source of early, easily measured PCa biomarkers in
ethnically diverse populations. Here we present our initial results in this effort.

Materials and Methods
Patient Plasma
Plasma samples were collected from 9 healthy male volunteers, and 12 PCa patients
(Table I). These 12 patients self defined themselves as AA (n=4), Caucasian (n=4) and
Hispanic (n=4). Blood was collected in vacuum tubes containing sodium heparin. The
tubes were centrifuged at 2000 x g for 7 minutes, and the plasma was then removed and
aliquoted for storage at -80 C. All samples were obtained in the course of IRB-approved
studies, following the documentation of informed consent in accordance with Loma
Linda University policies.
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Exosome Isolation
For plasma microvesicle samples, the commercially available ExoQuick (SBI,
Mountain View, CA) was employed as described by the vendor. Briefly, 100 μl of
plasma was incubated
with 100 L of ExoQuick solution followed by a 2 hr incubation at 4 °C followed by
centrifugation at 1500 x g for 30 minutes. After centrifugation the exosomes appear as a
beige or white pellet at the bottom of the vessel which is then reconstituted with 500 μl of
dH2O (Caby MP et al., 2005).

Exosome Quantification
To quantify the amount of exosomes released, we assessed the activity of
acetylcholinesterase, an enzyme that is associated with these vesicles (Savina A et al.,
2003). Acetylcholinesterase activity was assessed as described by Savina et al. (Savina A
et al., 2003). Briefly, 40 μl of the exosome fraction was suspended in 110 μl of PBS.
37.5 ml of this PBS-diluted exosome fraction was then added to individual wells on a 96well flat-bottomed microplate. 1.25 mM acetylthiocholine and 0.1 mM 5,50-dithiobis(2nitrobenzoic acid) were then added to exosome fractions in a final volume of 300 μl, and
the change in absorbance at 412 nm was monitored every 5 min for 30 min.

Protein Separation
For protein analysis, exosomal preparations were lysed using lysis buffer (50 mM
Tris (pH 7.5), 1% NP40, 0.25% DOC, 150 mM NaCl2, 1 mM PMSF, 10 μg/ml Aprotinin/
leupeptin/pepstatin, 20 mM NaF, 0.2 mM EGTA, 1 mM EDTA (pH 8.0), H2O). For
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protein concentrations the BCA assay (Pierce, Rockford, IL) was used. Proteins from
exosomes (20–40 μg) were separated using 12% Bis–Tris polyacrylamide gels.

In-Gel Trypsin Digestion and MS
Protein bands were excised manually and washed with 50% (v/v) methanol and
5% (v/v) acetic acid. The gel pieces were then dehydrated in acetonitrile and dried in a
SpeedVac concentrator (Savant, Farmingdale, NY). Proteins were reduced using 10 mM
dithiothreitol (DTT) in 100 mM ammonium bicarbonate for 30 min at room temperature.
The DTT solution was removed and the proteins were alkylated for 30 min at room
temperature using 100 mM iodoacetamide after which the gel pieces were dehydrated as
before. Gel pieces were rehydrated in 100 mM ammonium bicarbonate and then
dehydrated and dried as previously described. Proteins were tryptically digested using
MS grade trypsin (Promega, Madison, WI), added at a final concentration of 20 ng/ l to
fully cover the gel pieces. Digestion was performed at 37 °C overnight. Peptides were
recovered with 30 l, 50% (v/v) acetonitrile and 5% (v/v) formic acid twice. All
supernatants were pooled and dried in a SpeedVac concentrator for 1 hr.
Tryptic peptides were analyzed on a ThermoFinnigan LCQ Deca XP system that
includes a surveyor HPLC and a PicoView 500 (New Objective, Woburn, MA) for
performing nanoflow electrospray ionization. The flow of the surveyor HPLC pump was
split to achieve a 200–300 nanoliter/min flow exiting a PicoFrit column (New Objective)
packed with BioBasic C18 beads (10 cm, 5 l m, 300 A°). Samples were loaded onto a
Michrom Bioresources (Auburn, CA) cap-trap at 5 l l/min and washed with mobile phase
A (aqueous 2% acetonitrile with 0.1% formic acid). Peptides were then eluted onto the
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column and into the mass spectrometer using a gradient of 0–75% mobile phase B
(aqueous 90% acetonitrile with 0.1% formic acid). The mass spectra acquisition was
operated in the data dependent mode with one MSscan (300–1,500 m/z) and three
MS/MS scans of the most intense ions in the MS scan. We used the Sequest algorithm
implemented on the TurboSequest software package to identify proteins based on the
MS/MS spectra. The resulting Sequest hits were filtered based on the charge state and
Xcorr value to require Xcorr C 1.5, 2.0, and 2.5 for single, double, and triple charged
ions, respectively.
The MS/MS fragmentation spectra were searched against a current human protein
database (March 2009) containing 37,391 reference sequences. The search algorithms
Sequest (Eng et al., 1994), Mascot (Perkins et al., 1999), and X! TANDEM (Craig &
Beavis, 2004), were used to identify peptides and proteins. The significance of identified
peptides and proteins were determined using the Peptide-Prophet (Keller et al., 2002) and
Protein-Prophet (Nesvizhskii et al., 2003), respectively, algorithms as implemented in
Scaffold 2 (Proteome Software, Portland, OR). We included only peptides with a
Scaffold score of C 95% (5% false discovery rate) in the results.

Statistical Analysis
Multiple comparisons among different groups were calculated using Multiple
Analysis of Variance (MANOVA). A Student t-test (two-tailed) was used to evaluate the
significance of changes between control groups and experimental groups. Probability
values P<0.05 were considered statistically significant.
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Results
PCa Patients Exhibit Increased Exosome Numbers
We have previously demonstrated that cultured PCa cells release exosomes into
the extracellular milieu (Khan S et al., 2009). These small, membrane-vesicles are also
known to occur in the plasma as well as serum of cancer patients (Mitchell et al., 2009,
Koumangoye et al., 2011, Khan et al., 2012). Exosomes were therefore collected using
ExoQuick, and quantitated using the acetylcholinesterase enzymatic assay as we and
others have previously described (Johnstone, 2006, Khan S et al., 2011, Khan et al.,
2012). The mean plasma exosome levels varied significantly between the healthy control
subjects group and the different PCa patient groups (P< 0.001). However, there was no
significant difference in exosome quantity between the different PCa patient groups
(Figure 1).

Plasma-Derived Exosomes Contain Potential Biomarkers
Exosomes purified using ExoQuick from PCa patient plasma were characterized by
mass spectrometry. After the extraction from a preparative gel (Figure 2), proteins were
identified by LC-MS. The ten most abundant proteins identified were: Apolipoproteins,
Pregnancy Zone Protein, Macroglobulins, Keratin, Albumin Precursors, Haptoglobin,
Ceruloplasmins, Transferrin, Complement Proteins and Fibronectin (Table 2). Exosomal
proteins were next categorized for localization using Scaffold 2 software and found to
have the majority of their proteins determined to be intracellular (57%) and extracellular
(32%) with only 7% identified as cell membrane and 4% as indeterminate (Figure 3A).
Intracellular proteins present in the exosomes were next annotated for distribution and
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Figure 1.
Exosomal contents in PCa patients plasma samples by using the
acetylcholinesterase activity assay. Exosome levels were measured in plasma derived from
subjects representing Hispanic, African American and Caucasian PCa patients and control
collected from the three ethnic groups. Exosome levels were measured in serum derived
from 9 control, 4 Caucasian, 4 African American and 4 Hispanic subjects. Comparisons
were accomplished using MANOVA. (ns = not significant; **, p<0.05, statistically
significant).
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Patients
Figure 2. Exosomal proteins taken from PCa patients plasma were separated on a 4-12%
gradient SDS gel and stained with Coomassie brilliant blue. Gels are representative of 2
individual gels ran, showing 4 individuals of each ethnicity (C-Caucasian, AA-African
American, H-Hispanic, N-no PCa diagnosis). The major bands were analyzed by trypsin
digestion and LC-MS/MS mass spectrometry. Molecular-weight markers in kilodaltons
(Kda) are shown on the left.
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found to be mostly cytosolic (45%) and nuclear (24%), with the remaining 31% spread as
cytoskeletal (9%), Golgi (2%), ER (4%), mitochondrial (3%) and ubiquitous (13%)
(Figure 3B).
Proteomic Comparison Across Different Ethnicities
Exosome protein compositions were compared between those purified from
individuals with no diagnosis of PCa (non-Ca) and those with PCa (Figure 4A). The
exosomes from the non-Ca individuals provided the identities of 145 proteins (74+71)
while the exosomes collected from the PCa patients provided the identities of 184
proteins (71+113). Though there were 71 proteins found in common, we believe that the
analysis of the 74 non-Ca- specific and 113 PCa-specific proteins that could lead to the
discovery of a novel biomarkers, either a molecule which has become reduced as tumors
develop, identified from the unique non-Ca samples, or proteins with enhanced
expression as the tumor develops, identified from the unique PCa samples. When
comparing proteins identified from exosomes of our non-Ca volunteers to ethnicityspecific- associated PCa exosome proteins, the attribute most striking is the reduced
number of proteins held in common and the low number of proteins unique to each
ethnicity. The sum of the proteins from AA (82), Hispanic (149) and Caucasian (63) do
not add to the number of unique proteins from PCa (113) as there are a number of
common proteins found among these three ethnic groups.
Ethnicity-specific exosomal proteins were next investigated in order to define if any
of the 184 PCa-specific proteins, shared amongst the different ethnic groups were held in
common with all ethnicities, pairs of ethnicities, or definitive for a single ethnicity. Any
protein held in common would be a potential biomarker for PCa, while proteins that were
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Figure 3. PCa exosome protein localization. A. Exosomal proteins were categorized for
primary localization and found to have the majority of their proteins determined to be
intracellular and extracellular with only a small percentage of them in the cell membrane
or indeterminate. B. Intracellular proteins were next categorized as being cytosolic,
nuclear, cytoskeletal, golgi, ER, mitochondrial and ubiquitous in their distribution.
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Figure 4. Exosomal protein enrichment was monitored in each sample by mass
spectrometry. A. Cancer changes were assessed by first comparing PCa (CA) to the no
PCa (N) diagnosis control and then controls to each ethnicity specific exosomal proteome.
B. Intra-ethnicity was assessed by simply comparing within the ethnic-specific exosomal
proteomes. Venn diagrams show the comparisons in terms of exosome proteomes.
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only found in a specific ethnicity would be ideal as a putative biomarker for PCa in that
ethnicity. Figure 4B shows that there are 35 proteins held in common between the three
ethnic groups studied (Table 3) and there are 2, 24 and 13 shared proteins in
AA/Caucasian, AA/Hispanic and Caucasian/Hispanic respectively, that should be further
evaluated (Table 4). We also identified proteins that are unique, in our analysis, to each
individual ethnicity represented (Table 5 and Supplemental Table I).
Among all of these putative biomarkers are proteins of specific interest because
they have been previously described as cancer-associated proteins (Table 6). These
includes: DNA helicase homolog PIF1, Four and a Half LIM Domain 3, Glutathione S
transferase omega 2, Maternal embryonic leucine zipper kinase, Iroquois homeobox
protein 5, Leucine rich zipper containing 4, minichromosome maintenance complex
component 5, Mitochondrial tumor suppressor 1 isoform 4, nasopharyngeal epithelium
specific protein, Ubiquitin-like with PHD and ring finger domains, and Trinucleotide
repeat containing 6B isoform 3.

Discussion
The PSA test has been controversially utilized in PCa screening though initially it
was envisioned as a tool for evaluating treatment response. Its use as a screening tool
was driven by both the United States PCa burden and a need to detect its presence at an
early stage that would allow for curative treatment. Unfortunately, its use is believed to
have led to both over diagnosis and over treatment, and there remains an urgent need for
novel biomarkers to be found to supplement PSA for early PCa detection, management,
and treatment (Mazzola et al., 2011). Recent efforts in PCa biomarker discovery and
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evaluation remain scarce and those that have been published describe proteins that though
perhaps tumor specific, continue to show little specificity for PCa or require invasive or
surgical procedures (Welsh et al., 2003, Lin et al., 2013).
The goal of this work was to further evaluate clinical samples of PCa taken from
patients representing AA, Caucasian and Hispanic ethnicities for potential biomarkers of
tumor definition and aggressiveness. Collecting blood samples or a relatively noninvasive “liquid biopsy” could provide clinicians with a superior diagnostic and
therapeutic effectiveness-defining tool. Analyzing the secretome, or the secreted
biomolecules, from the developing tumor could more rapidly pinpoint the type of cancer
and best practice for treatment. Here we analyzed microvesicles called exosomes which
are ubiquitously released into the serum/plasma during tumorigenesis and have been
shown to be specifically enhanced in the serum of PCa patients compared to their
representative controls (Khan et al., 2012). Furthermore, recent studies have
demonstrated the importance of exosomal proteins in cancer cell function with a
particular interest paid to their role in tumorigenesis (Khan S et al., 2009, Park et al.,
2012, Demory Beckler et al., 2013, Ji et al., 2013). Our own recent work has defined the
role of the inhibitor of apoptosis protein Survivin, released in tumor exosomes, in cellular
proliferation, invasiveness and resistance to apoptosis (Khan S et al., 2009, Khan S et al.,
2011). By comparing the secretome of PCa patients representing various ethnic groups,
we may also gain key insights into tumor-associated molecular determinants of PCa
health disparities.
The molecular content of exosomes represents the molecular profile of the cell
type that released it (Properzi et al., 2013). Though a number of studies now describe the
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association of exosomal markers with several cancer types, only a few exosome based
diagnostic assays are currently available for clinical use (Properzi et al., 2013). The
present study was designed to dissect the PCa exosome from patients of varying
ethnicities and determine by mass spectrometry if there are ethnic differences in exosome
protein profiles. Though we found a large number of novel proteins that appeared to be
ethnicity-specific, additional studies with larger population cohorts are needed before one
could unequivocally state that these proteins will help define molecular determinants of
PCa health disparities. There may be other factors influencing the shedding of these
exosomes and their content such as age, diet, and environmental exposures that may
result from occupation or residence. The etiology of disease, access to healthcare, or the
compliance with interventional recommendations may be as important, or more
important, than the secretome that results from the above etiology. However, associating
molecular content with disease content may prove effective in early detection, resulting
in the saving of thousands of lives.
In this study, we were able to acquire a random sample of patients from AA,
Caucasian and Hispanic ethnicities and through molecular and cellular processes extract a
secretome from the microvesicles called exosomes. Using mass spectrometry we have
identified approximately 50 newly identified exosomal proteins that are added to the
exosome and tumor exosome databases. We are now beginning the arduous process of
evaluating one, or combinations of these, as putative PCa biomarkers. The list of
identified exosomal proteins includes three proteins with previous PCa association:
Iroquois Homeobox Protein 5 (IRX5), Mitochondrial Tumor Suppressor 1 Isoform 4
(MTS1), and Trinucleotide repeat containing 6B Isoform 3 (TNR6B) (Table 6).
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Interestingly, the expression of IRX4 protein, a similar protein to IRX5, has been shown
in normal prostate tissue and its knockdown is associated with enhanced growth (Nguyen
et al., 2012). However, its interaction with vitamin D receptor (VDR) is speculated to be
necessary for its anticancer function since in the absence of the VDR, PCa susceptibility
increases (Nguyen et al., 2012). MTS1, which is also known as a microtubule-associated
tumor suppressor, inhibits PCa cell proliferation, delays the progression of mitosis by
prolonging metaphase and reducing tumor growth (Ye et al., 2007). It too requires a
number of interacting proteins for its function and is not solely associated with PCa as it
has also been shown to play a role in breast, brain, ovarian, pancreas, colon, and head &
neck cancers (Ye et al., 2007). Of the three putative PCa-associated exosomal proteins,
TNR6B appears to hold the most promise. This protein has known interactions with
novel loci, single nucleotide polymorphisms (SNPs), on TET2 and SYK with interactions
modifying the risk for PCa (Tao et al., 2012). However, as in the case of MTS1 and
IRX5, additional studies are needed before these putative biomarkers may be used to
define risk, presence or even therapeutic response in PCa.
An important limitation of this study lies in the small number of patients that were
evaluated from each ethnicity. In spite of this, we were able to find differences in
exosomal protein contents between PCa patients and non-Ca controls, and between PCa
patients from the different ethnic groups. These results provide initial evidence that
exosomal profiling may not only yield new PCa biomarkers but also putative molecular
determinants of PCa health disparities. Additional studies with larger cohorts of
ethnically diverse patients and matched controls are guaranteed to identify unequivocally
exosome derived PCa biomarkers and health disparity determinants. Another limitation
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was that potentially important proteins were either too small to identify or masked by
other higher content proteins. In addition, it may also be problematic that proteins may
be present in both normal individuals and prostate cancer patients, and it is their
expression level that defines them as pathologic. This will always be the case with these
types of proteomic analyses. Also, patients were selected prior to undergoing any form
of therapy which would also be informative as the therapeutic stress causes different
proteins and pathways to be affected, potentially resulting in therapy-associated changes
in exosomal protein content. It should be noted, however, that to date, it has not been
established if treatment causes a radical change in exosome numbers or exosome
macromolecule content. Clearly, the clinical relevance of these initial observations
remain to be established, and it is too early to predict whether the potential exists to adopt
the three newly identified exosomal proteins in platforms for screening patients for the
presence of PCa. Studies with larger cohorts are currently underway in our laboratories
to evaluate whether these new findings will lead to the identification of molecular
determinants of PCa health disparities and ultimately to their reduction or elimination.
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CHAPTER 4
CONCLUSION
Prostate cancer (PCa) is the most frequently diagnosed non-skin cancer in men
and the second leading cause of male cancer deaths in the U.S., accounting for 240,890
new cases and 33,730 deaths in 2011(Brawley, 2012a). The incidence of the disease has
an uneven geographic distribution with the highest rates recorded in Australia, North and
Western Europe and The United States(GLOBOCAN). The incidence and mortality of
the disease is almost doubled among blacks compared to other ethnicities in the United
States(Parkin et al., 2005). An interesting note is that the disease incidence is lowest
among African Blacks although some have attributed that to the lack of availability of
proper statistics from this region of the world(Ferlay et al., 2010).
A plethora of risk factors for Prostate cancer have been questioned in the
literature including chronic inflammation of the prostate (infectious and non-infectious),
hormonal factors (elevated testosterone, leptin etc), smoking, dietary and genetic factors;
just to name a few. Smith et al described the link between the susceptibility gene HPC-1
(Hereditary Prostate Cancer) and an increased risk of developing prostate cancer,
especially in younger patients(Smith et al., 1996). Overall, prostate cancer is believed to
be a disease of multifactorial origin.
Prostate Specific Antigen (PSA) combined with a digital rectal exam has
remained the mainstay of screening for prostate cancer for the past two to three decades.
PSA was first described as a marker for human semen in forensics but it was
subsequently demonstrated in the serum of men with prostate disease(Stamey et al.,
1987). The test was however intended for surveillance of diagnosed prostate cancer
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patients. There was a sharp rise in newly diagnosed cases in the early 1990’s attributed
to the introduction of PSA as a screening test for prostate cancer. Coincident with this
increase in the number of new cases diagnosed was a pathologic migration toward a more
favorable (early disease) stage at diagnosis(Derweesh et al., 2004). Non-palpable
prostate cancer (and therefore perhaps clinically treatable disease) now accounts for 7080% of newly diagnosed cases according to the same authors. This may at least in part
explain why the combined 5 and 10 year survival for all stages of prostate cancer is
currently at 99% and 91% respectively. The true clinical value/advantage of using serum
PSA as a screening test has been recently called into question. While the use of this test
has increased the proportion of patients with lower tumor stage at the time of diagnosis,
its value is still debated because of its limitations: 1) the cut-off PSA value of 4.0 ng/ml
fails to detect a significant number of prostate tumors; 2) PSA screening has not been
demonstrated to improve health outcomes, particularly in older men; 3) PSA is not
specific for PCa since its levels can be elevated in patients with benign prostatic
hyperplasia (BPH) and prostatitis, leading to a false-positive finding of up to 60-80% of
prostate biopsies; and 4) obesity lowers PSA levels(Werny et al., 2007), which in theory
could lead to delayed detection of PCa and worse clinical outcome. Moreover, the lack
of specificity of PSA as a screening tool has also led to too many and sometimes
unnecessary diagnostic (biopsies) and therapeutic procedures. The conclusions from the
European Trial of Prostate-Cancer screening was that 1410 screenings/biopsies had to be
performed and 48 additional cases treated in order to prevent one death from prostate
cancer(Schroder et al., 2009). It is the realization of this need that has led us to devote
effort to the identification of novel biomarkers that, will enhance early PaCa detection,
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management and therapeutic response. We recognized that we are not alone in this quest
but our motivation comes even more so from the fact that efforts in this direction are at
the best promising but inconclusive.
The “holy grail” of PCa diagnosis and management is to determine an optimal
combination of clinical indicators or biomarkers that could detect tumors early with high
specificity/sensitivity and with limited invasiveness, and that could accurately predict
which diagnosed men will develop aggressive tumors requiring treatment, and which
treated men are likely to undergo recurrence and develop advanced, chemoresistant
disease. In spite of the availability of a plethora of gene products considered as promising
PCa biomarkers, it is recognized that their combined use with the available clinical
information is still insufficient for early diagnosis and for guiding individualized
therapeutic interventions and predicting outcomes. Their main limitation is that they lack
specificity and some may require invasive procedures such as biopsies. However, there
is growing interest in using proteomics approaches to identify tumor-derived serum
microvesicles called exosomes and their content, as serological biomarkers. This interest
stems from the notion that these blood components are considered “sensors” of molecular
events associated with tumorigenesis. The proteomic and ribonucleic make-up of tumor
derived exosomes, offers us a snapshot into the ‘internal milieu’ of the tumor
microenvironment(Yang & Robbins, 2011).
The very first step toward this journey of novel Biomarker discovery for prostate
cancer commences with a descriptive analysis of the protein make-up of exosomes
derived from the sera of patients with prostate cancer. By comparing this to the
proteomic profile of exosomes from non-cancer subjects, one hopes to begin to define
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potential biomarker targets. Moreover, comparing proteomic profiles across different
ethnicities may just unmask molecular mechanisms involved in conferring a more
aggressive disease phenotype among blacks of African descent.
This quest for a novel biomarker has to begin with a complete and exhaustive
seroproteomic profiling of the entire proteome of serum derived exosomes of PCa
patients. A secondary but equally important objective is to identify molecular marker(s)
that might begin to explain the higher incidence and relatively higher disease severity and
mortality in the black population.
The proposed projects associated with this dissertation focused on a critical need
in the fight against PCa: the identification of novel and promising blood biomarkers that
could enhance the early detection and management of PCa and the identification of
molecular markers that may begin to explain the ethnic disparity of the disease.
Most efforts on the identification of candidate PCa biomarkers, have emphasized
the analysis of differential gene expression in tumor tissues, methylation patterns, or
single nucleotide polymorphisms (SNPs) (Saif et al., 2005, Gonda et al., 2011, Gonda &
Saif, 2011, Smith et al., 2012). While these efforts are necessary and provide important
clues for understanding biological mechanisms associated with PCa, it is also imperative
to develop innovative, non-invasive approaches that analyze indirectly and early in the
disease process, the molecular profile of prostate tumors. Recent studies have shown that
small membrane-bound vesicles called exosomes constitute the latest mode of
intercellular information transfer or communication (Kharaziha et al., 2012, Vlassov et
al., 2012). This exchange of molecular information is facilitated by their unique
composition, which is enriched with enzymes, structural proteins, adhesion molecules,
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lipid rafts, microRNAs (miRNAs) and RNAs. An international database (exocarta.org) of
exosome biomolecules has recorded well over 4,000 proteins and over 2,000 RNA’s.
Importantly, cancer cells have been shown to secrete more exosomes than do normal
tissues indicating that exosomes can be used as diagnostic markers and their active
secretion has functional implications. Not only do cancer cells release more exosomes
than normal cells but their biomolecular make-up reflects their cell/tissue of origin(Ge et
al., 2012).
The studies that have been undertaken in this process have described for the first
time the entire proteomic make-up of exosomes from PCa patients using exo-profiling
and seroproteomics approaches, currently considered the most promising strategy for the
identification of serum biomarkers in human cancers (Tjalsma et al., 2008, Tan et al.,
2009, Kobold, Luetkens, et al., 2010, Kobold, Lutkens, et al., 2010). We are pleased
with the works success but in no way believe we have done any more than just begun to
understand a better method for early detection of cancer in general and prostate cancer in
specifics.

107

REFERENCES
A. Esh M.A., N. Azizi, M. El Naggar, E. Khalil, L. Sherief. (2011). Prognostic
significance of survivin in pediatric acute lymphoblastic leukemia. Indian journal
of hematology & blood transfusion : an official journal of Indian Society of
Hematology and Blood Transfusion 27, 18-25.
Adamkov M., Kajo K., Vybohova D., Krajcovic J., Stuller F. and Rajcani J. (2012).
Correlations of survivin expression with clinicomorphological parameters and
hormonal receptor status in breast ductal carcinoma. Neoplasma 59, 30-37.
Adams M., Navabi H., Croston D., Coleman S., Tabi Z., Clayton A., Jasani B. and Mason
M.D. (2005). The rationale for combined chemo/immunotherapy using a toll-like
receptor 3 (tlr3) agonist and tumour-derived exosomes in advanced ovarian
cancer. Vaccine 23, 2374-2378.
Adida C., Recher C., Raffoux E., Daniel M.T., Taksin A.L., Rousselot P., Sigaux F.,
Degos L., Altieri D.C. and Dombret H. (2000). Expression and prognostic
significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111,
196-203.
Ahmed M.B., Shehata H.H., Moussa M. and Ibrahim T.M. (2012). Prognostic
significance of survivin and tumor necrosis factor-alpha in adult acute
lymphoblastic leukemia. Clinical Biochemistry 45, 112-116.
Aizer A.A., Wilhite T.J., Chen M.H., Graham P.L., Choueiri T.K., Hoffman K.E., Martin
N.E., Trinh Q.D., Hu J.C. and Nguyen P.L. (2014). Lack of reduction in racial
disparities in cancer-specific mortality over a 20-year period. Cancer 120, 15321539.
Aleckovic M. and Kang Y. (2015). Regulation of cancer metastasis by cell-free mirnas.
Biochimica et biophysica acta 1855, 24-42.
Altieri D.C. (2003). Survivin, versatile modulation of cell division and apoptosis in
cancer. Oncogene 22, 8581-8589.
Altieri D.C. (2006). The case for survivin as a regulator of microtubule dynamics and
cell-death decisions. Current Opinion in Cell Biology 18, 609-615.
Altieri D.C. (2008). Survivin, cancer networks and pathway-directed drug discovery.
Nature Reviews 8, 61-70.
Altieri DC. (2003a). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3,
46-54.
Altieri DC. (2003b). Survivin, versatile modulation of cell division and apoptosis in
cancer. Oncogene 22, 8581-8589.

108

Amarnath S., Mangus C.W., Wang J.C.M., Wei F., He A., Kapoor V., Foley J.E., Massey
P.R., Felizardo T.C., Riley J.L., Levine B.L., June C.H., Medin J.A. and Fowler
D.H. (2011). The pdl1-pd1 axis converts human th1 cells into regulatory t cells.
Science Translational Medicine 3, 111ra120.
Andersen M.H., Svane I.M., Becker J.C. and Straten P.t. (2007). The universal character
of the tumor-associated antigen survivin. Clinical Cancer Research 13, 59915994.
Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., Pomel C.,
Lhomme C., Escudier B., Le Chevalier T., Tursz T., Amigorena S., Raposo G.,
Angevin E. and Zitvogel L. (2002). Malignant effusions and immunogenic
tumour-derived exosomes. Lancet 360, 295-305.
Aspe J.R., Diaz Osterman C.J., Jutzy J.M., Deshields S., Whang S. and Wall N.R. (2014).
Enhancement of gemcitabine sensitivity in pancreatic adenocarcinoma by novel
exosome-mediated delivery of the survivin-t34a mutant. Journal of extracellular
vesicles 3.
Asuncion Valenzuela M.M., Castro I., Gonda A., Diaz Osterman C.J., Jutzy J.M., Aspe
J.R., Khan S., Neidigh J.W. and Wall N.R. (2015). Cell death in response to
antimetabolites directed at ribonucleotide reductase and thymidylate synthase.
OncoTargets and therapy 8, 495-507.
Banks D.P., Plescia J., Altieri D.C., Chen J., Rosenberg S.H., Zhang H. and Ng S.C.
(2000). Survivin does not inhibit caspase-3 activity. Blood 96, 4002-4003.
Basu A., Banerjee H., Rojas H., Martinez S.R., Roy S., Jia Z., Lilly M.B., De Leon M.
and Casiano C.A. (2011). Differential expression of peroxiredoxins in prostate
cancer: Consistent upregulation of prdx3 and prdx4. The Prostate 71, 755-765.
Bernardo P.S., Reis F.R.d.S. and Maia R.C. (2012). Imatinib increases apoptosis index
through modulation of survivin subcellular localization in the blast phase of cml
cells. Leukemia Research 36, 1510-1516.
Beydoun H.A. and Beydoun M.A. (2008). Predictors of colorectal cancer screening
behaviors among average-risk older adults in the united states. Cancer causes &
control : CCC 19, 339-359.
Bhatnagar S., Shinagawa K., Castellino F.J. and Schorey J.S. (2007). Exosomes released
from macrophages infected with intracellular pathogens stimulate a
proinflammatory response in vitro and in vivo. Blood 110, 3234-3244.
Bjartell A., Montironi R., Berney D.M. and Egevad L. (2011). Tumour markers in
prostate cancer ii: Diagnostic and prognostic cellular biomarkers. Acta Oncol 50
Suppl 1, 76-84.

109

Boidot R., Vegran F. and Lizard-Nacol S. (2009). Predictive value of survivin alternative
transcript expression in locally advanced breast cancer patients treated with
neoadjuvant chemotherapy. Int J Mol Med 23, 285-291.
Bradley L.A., Palomaki G.E., Gutman S., Samson D. and Aronson N. (2013).
Comparative effectiveness review: Prostate cancer antigen 3 testing for the
diagnosis and management of prostate cancer. J Urol 190, 389-398.
Brawley O.W. (2012a). Prostate cancer epidemiology in the united states. World J Urol
30, 195-200.
Brawley O.W. (2012b). Prostate cancer epidemiology in the united states. World J Urol
30, 195-200.
Bryant R.J. and Lilja H. (2014). Emerging psa-based tests to improve screening. Urol
Clin North Am 41, 267-276.
Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G and Bonnerot C. (2005).
Exosomal like vesicles are present in human blood plasma. Int Immunol 17, 879887.
Carter B.Z., Qiu Y., Huang X., Diao L., Zhang N., Coombes K.R., Mak D.H., Konopleva
M., Cortes J., Kantarjian H.M., Mills G.B., Andreeff M. and Kornblau S.M.
(2012). Survivin is highly expressed in cd34(+)38(-) leukemic stem/progenitor
cells and predicts poor clinical outcomes in aml. Blood 120, 173-180.
Chang K.J., Parasher G., Christie C., Largent J. and Anton-Culver H. (2005). Risk of
pancreatic adenocarcinoma: Disparity between african americans and other
race/ethnic groups. Cancer 103, 349-357.
Chang R.T., Kirby R. and Challacombe B.J. (2012). Is there a link between bph and
prostate cancer? The Practitioner 256, 13-16, 12.
Church D.N. and Talbot D.C. (2012). Survivin in solid tumors: Rationale for
development of inhibitors. Current oncology reports 14, 120-128.
Clayton A., Turkes A., Navabi H., Mason M.D. and Tabi Z. (2005). Induction of heat
shock proteins in b-cell exosomes. J Cell Sci 118, 3631-3638.
Council N.R. (1982). Diet, nutrition, and cancer.
Craig R. and Beavis R.C. (2004). Tandem: Matching proteins with tandem mass spectra.
Bioinformatics 20, 1466-1467.
Croswell J.M., Kramer B.S. and Crawford E.D. (2011). Screening for prostate cancer
with psa testing: Current status and future directions. Oncology (Williston Park)
25, 452-460, 463.

110

Darwish-Yassine M., Berenji M., Wing D., Copeland G., Demers R.Y., Garlinghouse C.,
Fagerlin A., Newth G.E., Northouse L., Holmes-Rovner M., Rovner D., Sims J.
and Wei J.T. (2014). Evaluating long-term patient-centered outcomes following
prostate cancer treatment: Findings from the michigan prostate cancer survivor
study. Journal of cancer survivorship : research and practice 8, 121-130.
De Pergola G. and Silvestris F. (2013). Obesity as a major risk factor for cancer. Journal
of obesity 2013, 291546.
Dedić Plavetić N., Jakić-Razumović J., Kulić A. and Vrbanec D. (2013). Prognostic
value of proliferation markers expression in breast cancer. Med Oncol 30, 1-13.
Dehal A., Abbas A. and Johna S. (2013). Racial disparities in clinical presentation,
surgical treatment and in-hospital outcomes of women with breast cancer:
Analysis of nationwide inpatient sample database. Breast cancer research and
treatment.
Demory Beckler M., Higginbotham J.N., Franklin J.L., Ham A.J., Halvey P.J., Imasuen
I.E., Whitwell C., Li M., Liebler D.C. and Coffey R.J. (2013). Proteomic analysis
of exosomes from mutant kras colon cancer cells identifies intercellular transfer
of mutant kras. Molecular & cellular proteomics : MCP 12, 343-355.
Denmeade SR. (1996). Apoptotic pathways in normal prostate and prostate cancer. The
Prostate 1, 120-125.
Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W and Geuze HJ. (2000). Exosome:
From internal vesicle of the multivesicular body to intercellular signaling device.
J Cell Sci 113, 3365-3374.
Derweesh I.H., Kupelian P.A., Zippe C., Levin H.S., Brainard J., Magi-Galluzzi C.,
Myles J., Reuther A.M. and Klein E.A. (2004). Continuing trends in pathological
stage migration in radical prostatectomy specimens. Urologic oncology 22, 300306.
Ding X.Z., Tong W.G. and Adrian T.E. (2001). Cyclooxygenases and lipoxygenases as
potential targets for treatment of pancreatic cancer. Pancreatology 1, 291-299.
Dohi T., Beltrami E., Wall N.R., Plescia J. and Altieri D.C. (2004a). Mitochondrial
survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114, 11171127.
Dohi T., Beltrami E., Wall N.R., Plescia J. and Altieri D.C. (2004b). Mitochondrial
survivin inhibits apoptosis and promotes tumorigenesis. The Journal of Clinical
Investigation 114, 1117-1127.
Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., Marusawa H., Zou H.,
Armstrong R., Matsuzawa S., Salvesen G.S., Reed J.C. and Altieri D.C. (2004).
An iap-iap complex inhibits apoptosis. J Biol Chem 279, 34087-34090.
111

Dong Z., Venkatachalam M.A., Wang J., Patel Y., Saikumar P., Semenza G.L., Force T.
and Nishiyama J. (2001). Up-regulation of apoptosis inhibitory protein iap-2 by
hypoxia. Hif-1-independent mechanisms. J Biol Chem 276, 18702-18709.
Duijvesz D., Luider T., Bangma C.H. and Jenster G. (2011). Exosomes as biomarker
treasure chests for prostate cancer. European urology 59, 823-831.
El-Attar H.A., Kandil M.H., El-Kerm Y.M. and El-Ghandour M.K. (2010). Comparison
of serum survivin and alpha fetoprotein in egyptian patients with hepatocellular
carcinoma associated with hepatitis c viral infection. Asian Pac J Cancer Prev 11,
897-903.
Eng J.K., McCormack A.L. and Yates J.R. (1994). An approach to correlate tandem mass
spectral data of peptides with amino acid sequences in a protein database. Journal
of the American Society for Mass Spectrometry 5, 976-989.
Faraday M., Hubbard H., Kosiak B. and Dmochowski R. (2009). Staying at the cutting
edge: A review and analysis of evidence reporting and grading; the
recommendations of the american urological association. BJU international 104,
294-297.
Ferlay J., Shin H.R., Bray F., Forman D., Mathers C. and Parkin D.M. (2010). Estimates
of worldwide burden of cancer in 2008: Globocan 2008. International journal of
cancer. Journal international du cancer 127, 2893-2917.
Fine S.W. and Epstein J.I. (2008). A contemporary study correlating prostate needle
biopsy and radical prostatectomy gleason score. J Urol 179, 1335-1338;
discussion 1338-1339.
Fiorentino M., Capizzi E. and Loda M. (2010). Blood and tissue biomarkers in prostate
cancer: State of the art. Urol Clin North Am 37, 131-141, Table of Contents.
Fortugno P., Wall N.R., Giodini A., O'Connor D.S., Plescia J., Padgett K.M., Tognin S.,
Marchisio P.C. and Altieri D.C. (2002). Survivin exists in immunochemically
distinct subcellular pools and is involved in spindle microtubule function. Journal
of Cell Science 115, 575-585.
Fradet Y. (2009). Biomarkers in prostate cancer diagnosis and prognosis: Beyond
prostate-specific antigen. Curr Opin Urol 19, 243-246.
Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C.
and Partin A.W. (2005). Risk of prostate cancer-specific mortality following
biochemical recurrence after radical prostatectomy. JAMA : the journal of the
American Medical Association 294, 433-439.
Fukuda S. and Pelus L.M. (2006). Survivin, a cancer target with an emerging role in
normal adult tissues. Mol Cancer Ther 5, 1087-1098.

112

Fulda S. (2009). Inhibitor of apoptosis proteins in hematological malignancies. Leukemia
23, 467-476.
Fulda S. (2012). Exploiting inhibitor of apoptosis proteins as therapeutic targets in
hematological malignancies. Leukemia 26, 1155-1165.
Ge R., Tan E., Sharghi-Namini S. and Asada H.H. (2012). Exosomes in cancer
microenvironment and beyond: Have we overlooked these extracellular
messengers? Cancer microenvironment : official journal of the International
Cancer Microenvironment Society 5, 323-332.
Ginestra A, Miceli D, Dolo V, Romano FM and Vittorelli ML. (1999). Membrane
vesicles in ovarian cancer fluids: A new potential marker. Anticancer Res 19,
3439-3445.
Ginestra A, La Placa MD, Saladino F, Cassara D, Nagase H and Vittorelli ML. (1998).
The amount of proteolytic content of vesicles shed by human cancer cell lines
correlates with their in vitro invasiveness. Anticancer Res 18, 3433-3437.
GLOBOCAN. Cancer fact sheets.
Gonda T.A. and Saif M.W. (2011). Early detection and screening of pancreatic cancer.
Highlights from the "2011 asco gastrointestinal cancers symposium". San
francisco, ca, USA. January 20-22, 2011. JOP 12, 83-85.
Gonda T.A., Lucas A. and Saif M.W. (2011). Screening and detection of pancreatic
cancer. Highlights from the "2011 asco annual meeting". Chicago, il, USA; june
3-7, 2011. JOP 12, 322-324.
Gordis L. (1993). The pancreas, biology, pathobiology and disease. Raven Press. New
York, NY.
Greening D.W., Gopal S.K., Xu R., Simpson R.J. and Chen W. (2015). Exosomes and
their roles in immune regulation and cancer. Seminars in cell & developmental
biology.
Grzybowska-Izydorczyk O., Cebula B., Robak T. and Smolewski P. (2010). Expression
and prognostic significance of the inhibitor of apoptosis protein (iap) family and
its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 46, 800-810.
Guessous I., Dash C., Lapin P., Doroshenk M., Smith R.A., Klabunde C.N. and National
Colorectal Cancer Roundtable Screening Among the 65 Plus Task G. (2010).
Colorectal cancer screening barriers and facilitators in older persons. Preventive
medicine 50, 3-10.
Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J,
Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H and Qui Y.

113

(2006). Regulation of androgen receptor activity by tyrosine phosphorylation.
Cancer Cell 10, 309-319.
Guthrie N. and Carroll K.K. (1999). Specific versus non-specific effects of dietary fat on
carcinogenesis. Progress in lipid research 38, 261-271.
Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I. and Walsh P.C. (2003).
Biochemical (prostate specific antigen) recurrence probability following radical
prostatectomy for clinically localized prostate cancer. J Urol 169, 517-523.
Hayanga A.J. (2005). Risk of pancreatic adenocarcinoma: Disparity between african
americans and other race/ethnic groups. Cancer 104, 2530-2531; author reply
2531.
Hoffman R.M., Gilliland F.D., Eley J.W., Harlan L.C., Stephenson R.A., Stanford J.L.,
Albertson P.C., Hamilton A.S., Hunt W.C. and Potosky A.L. (2001). Racial and
ethnic differences in advanced-stage prostate cancer: The prostate cancer
outcomes study. Journal of the National Cancer Institute 93, 388-395.
Howell SB. (2000). Resistance to apoptosis in prostate cancer cells. Mol Urol 4, 225-229.
Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S. and Rivoltini L. (2008).
Tumour-released exosomes and their implications in cancer immunity. Cell Death
Differ 15, 80-88.
Jadav S., Rajan S.S., Abughosh S. and Sansgiry S.S. (2015). The role of socioeconomic
status and health care access in breast cancer screening compliance among
hispanics. Journal of public health management and practice : JPHMP.
Jemal A., Siegel R., Xu J. and Ward E. (2010). Cancer statistics, 2010. CA: a cancer
journal for clinicians 60, 277-300.
Jemal A., Bray F., Center M.M., Ferlay J., Ward E. and Forman D. (2011). Global cancer
statistics. CA: a cancer journal for clinicians 61, 69-90.
Ji H., Greening D.W., Barnes T.W., Lim J.W., Tauro B.J., Rai A., Xu R., Adda C.,
Mathivanan S., Zhao W., Xue Y., Xu T., Zhu H.J. and Simpson R.J. (2013).
Proteome profiling of exosomes derived from human primary and metastatic
colorectal cancer cells reveal differential expression of key metastatic factors and
signal transduction components. Proteomics 13, 1672-1686.
Johnson R.H., Chien F.L. and Bleyer A. (2013). Incidence of breast cancer with distant
involvement among women in the united states, 1976 to 2009. JAMA : the journal
of the American Medical Association 309, 800-805.
Johnstone R.M. (2006). Exosomes biological significance: A concise review. Blood Cells
Mol Dis 36, 315-321.

114

Jutzy J.S., Khan S., Asuncion-Valenzuela M., Milford T.-A., Payne K. and Wall N.
(2013). Tumor-released survivin induces a type-2 t cell response and decreases
cytotoxic t cell function, in vitro. Cancer Microenvironment 6, 57-68.
Kalla Singh S., Tan Q.W., Brito C., De Leon M., Garberoglio C. and De Leon D. (2010).
Differential insulin-like growth factor ii (igf-ii) expression: A potential role for
breast cancer survival disparity. Growth hormone & IGF research : official
journal of the Growth Hormone Research Society and the International IGF
Research Society 20, 162-170.
Kamihira S., Yamada Y., Hirakata Y., Tomonaga M., Sugahara K., Hayashi T., Dateki
N., Harasawa H. and Nakayama K. (2001). Aberrant expression of caspase
cascade regulatory genes in adult t-cell leukaemia: Survivin is an important
determinant for prognosis. Br J Haematol 114, 63-69.
Karami S., Young H.A. and Henson D.E. (2007). Earlier age at diagnosis: Another
dimension in cancer disparity? Cancer detection and prevention 31, 29-34.
Kardasevic A. and Delic-Redzepagic E. (2014). Qualitative approach and treatment of
patients with prostate cancer in cantonal hospital bihac during two years period.
Materia socio-medica 26, 59-61.
Kasuga M., Ueki K., Tajima N., Noda M., Ohashi K., Noto H., Goto A., Ogawa W.,
Sakai R., Tsugane S., Hamajima N., Nakagama H., Tajima K., Miyazono K. and
Imai K. (2013). Report of the japan diabetes society/japanese cancer association
joint committee on diabetes and cancer. Cancer science 104, 965-976.
Keller A., Nesvizhskii A.I., Kolker E. and Aebersold R. (2002). Empirical statistical
model to estimate the accuracy of peptide identifications made by ms/ms and
database search. Analytical chemistry 74, 5383-5392.
Keller S, Sanderson MP, Stoeck A and Altevogt P. (2006). Exosomes: From biogenesis
and secretion to biological function. Immunol Lett 107, 102-108.
Kelly R.L.-C., Ariel; Citrin, Deborah; Janik, John; Morris, John. (2011). Impacting
tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Molecular
Cancer Research 10.
Khan S., Bennit H.F. and Wall N.R. (2015). The emerging role of exosomes in survivin
secretion. Histology and histopathology 30, 43-50.
Khan S., Bennit H.F., Turay D., Perez M., Mirshahidi S., Yuan Y. and Wall N.R. (2014).
Early diagnostic value of survivin and its alternative splice variants in breast
cancer. BMC cancer 14, 176.
Khan S., Aspe J.R., Asumen M.G., Almaguel F., Odumosu O., Acevedo-Martinez S., De
Leon M., Langridge W.H. and Wall N.R. (2009). Extracellular, cell-permeable

115

survivin inhibits apoptosis while promoting proliferative and metastatic potential.
Br J Cancer 100, 1073-1086.
Khan S., Jutzy J.M., Valenzuela M.M., Turay D., Aspe J.R., Ashok A., Mirshahidi S.,
Mercola D., Lilly M.B. and Wall N.R. (2012). Plasma-derived exosomal survivin,
a plausible biomarker for early detection of prostate cancer. PloS one 7, e46737.
Khan S, Jutzy JMS, Aspe JR, McGregor DW, Neidigh JW and Wall NR. (2011).
Survivin is released from cancer cells via exosomes. Apoptosis 16, 1-12.
Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S, De Leon
M, Langridge WH and Wall NR. (2009). Extracellular, cell-permeable survivin
inhibits apoptosis while promoting proliferative and metastatic potential. Brit J
Cancer 100, 1073-1086.
Kharaziha P., Ceder S., Li Q. and Panaretakis T. (2012). Tumor cell-derived exosomes: A
message in a bottle. Biochimica et biophysica acta.
Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S and Shiina H. (2004). Expression of
the survivin gene in prostate cancer: Correlation with clinicopathological
characteristics, proliferative activity and apoptosis. J Urol 171, 1855-1860.
Klein EA and Kupelian PA. (2003). Localised prostate cancer: Radiation or surgery? .
Urol Clin North Am 30, 315-330.
Kobold S., Lutkens T., Cao Y., Bokemeyer C. and Atanackovic D. (2010).
Autoantibodies against tumor-related antigens: Incidence and biologic
significance. Hum Immunol 71, 643-651.
Kobold S., Luetkens T., Cao Y., Bokemeyer C. and Atanackovic D. (2010). Prognostic
and diagnostic value of spontaneous tumor-related antibodies. Clinical &
developmental immunology 2010, 721531.
Koike H., Sekine Y., Kamiya M., Nakazato H. and Suzuki K. (2008). Gene expression of
survivin and its spliced isoforms associated with proliferation and aggressive
phenotypes of prostate cancer. Urology 72, 1229-1233.
Koike H, Sekine Y, Kamiya M, Nakazato H and Suzuki K. (2008). Gene expression of
survivin and its spliced isoforms associated with proliferation and aggressive
phenotypes of prostate cancer. Urology 72, 1229-1233.
Kono S. (2010). [host and environmental factors predisposing to cancer development].
Gan to kagaku ryoho. Cancer & chemotherapy 37, 571-576.
Koumangoye R.B., Sakwe A.M., Goodwin J.S., Patel T. and Ochieng J. (2011).
Detachment of breast tumor cells induces rapid secretion of exosomes which
subsequently mediate cellular adhesion and spreading. PloS one 6, e24234.

116

Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and
Reed JC. (1996). Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1
expression in prostate cancers. Am J Pathol 148, 1567-1576.
Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi
OP, Shabaik A, Vitiello A, Peehl D, Gao GJ and Reed JC. (2003). Elevated
expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9,
4914-4925.
Kumar B., Yadav A., Lang J.C., Cipolla M.J., Schmitt A.C., Arradaza N., Teknos T.N.
and Kumar P. (2012). Ym155 reverses cisplatin resistance in head and neck
cancer by decreasing cytoplasmic survivin levels. Molecular Cancer Therapeutics
11, 1988-1998.
Li F. (2004). Role of survivin and its splice variants in tumorigenesis. British Journal of
Cancer 92, 212-216.
Li F. and Ling X. (2006). Survivin study: An update of "what is the next wave?". Journal
of Cellular Physiology 208, 476-486.
Li F., Yang J., Ramnath N., Javle M.M. and Tan D. (2005). Nuclear or cytoplasmic
expression of survivin: What is the significance? International journal of cancer.
Journal international du cancer 114, 509-512.
Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C. and Altieri D.C.
(1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature
396, 580-584.
Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio
PC and Altieri DC. (1999). Pleiotropic cell-division defects and apoptosis induced
by interference with survivin function. Nat Cell Biol 1, 461-466.
Li Y, Che M, Bhagat S, Ellis K, Kucuk O, Doerge DR, Abrams J, Cher ML and Sarkar
FH. (2004). Regulation of gene expression and inhibition of experimental prostate
cancer bone metastasis by dietary genistein. Neoplasia 6, 354-363.
Lin Q., Tan H.T., Lim H.S. and Chung M.C. (2013). Sieving through the cancer
secretome. Biochimica et biophysica acta 1834, 2360-2371.
Lladser A., Párraga M., Quevedo L., Carmen Molina M., Silva S., Ferreira A., Billetta R.
and G. Quest A.F. (2006). Naked DNA immunization as an approach to target the
generic tumor antigen survivin induces humoral and cellular immune responses in
mice. Immunobiology 211, 11-27.
Loeb S., Vonesh E.F., Metter E.J., Carter H.B., Gann P.H. and Catalona W.J. (2011).
What is the true number needed to screen and treat to save a life with prostatespecific antigen testing? Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 29, 464-467.
117

Lowenfels A.B. and Maisonneuve P. (2006). Epidemiology and risk factors for
pancreatic cancer. Best practice & research. Clinical gastroenterology 20, 197209.
Lu S, Liu M, Epner DE and Tsai MJ. (1999). Androgen regulation of the cyclindependent kinase inhibitor p21 gene through an androgen response element in the
proximal promoter. Mol Endocrinol 13, 376-384.
Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I. and Reed J.C.
(2003). Hbxip functions as a cofactor of survivin in apoptosis suppression. The
EMBO journal 22, 2729-2740.
Mazzola C.R., Ghoneim T. and Shariat S.F. (2011). [emerging biomarkers for the
diagnosis, staging and prognosis of prostate cancer]. Prog Urol 21, 1-10.
Mera S., Magnusson M., Tarkowski A. and Bokarewa M. (2008). Extracellular survivin
up-regulates adhesion molecules on the surface of leukocytes changing their
reactivity pattern. Journal of Leukocyte Biology 83, 149-155.
Mikolajczyk S.D., Song Y., Wong J.R., Matson R.S. and Rittenhouse H.G. (2004). Are
multiple markers the future of prostate cancer diagnostics? Clin Biochem 37, 519528.
Mitchell P.J., Welton J., Staffurth J., Court J., Mason M.D., Tabi Z. and Clayton A.
(2009). Can urinary exosomes act as treatment response markers in prostate
cancer? J Transl Med 7, 4.
Morrison D.J., Hogan L.E., Condos G., Bhatla T., Germino N., Moskowitz N.P., Lee L.,
Bhojwani D., Horton T.M., Belitskaya-Levy I., Greenberger L.M., Horak I.D.,
Grupp S.A., Teachey D.T., Raetz E.A. and Carroll W.L. (2012). Endogenous
knockdown of survivin improves chemotherapeutic response in all models.
Leukemia 26, 271-279.
Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A,
Tominaga F, Yamanaka K, Kudoh M and Sasamata M. (2007). Ym155, a novel
small-molecule survivin suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer research 67, 8014-8021.
Nakamura K., Nagata C., Wada K., Tamai Y., Tsuji M., Takatsuka N. and Shimizu H.
(2011). Cigarette smoking and other lifestyle factors in relation to the risk of
pancreatic cancer death: A prospective cohort study in japan. Japanese journal of
clinical oncology 41, 225-231.
Necochea-Campion R., Chen C.S., Mirshahidi S., Howard F.D. and Wall N.R. (2013).
Clinico-pathologic relevance of survivin splice variant expression in cancer.
Cancer letters 339, 167-174.

118

Nesvizhskii A.I., Keller A., Kolker E. and Aebersold R. (2003). A statistical model for
identifying proteins by tandem mass spectrometry. Analytical chemistry 75, 46464658.
Nguyen H.H., Takata R., Akamatsu S., Shigemizu D., Tsunoda T., Furihata M.,
Takahashi A., Kubo M., Kamatani N., Ogawa O., Fujioka T., Nakamura Y. and
Nakagawa H. (2012). Irx4 at 5p15 suppresses prostate cancer growth through the
interaction with vitamin d receptor, conferring prostate cancer susceptibility.
Human molecular genetics 21, 2076-2085.
Nilsson J., Skog J., Nordstrand A., Baranov V., Mincheva-Nilsson L., Breakefield X.O.
and Widmark A. (2009). Prostate cancer-derived urine exosomes: A novel
approach to biomarkers for prostate cancer. Br J Cancer 100, 1603-1607.
Park E., Gang E.J., Hsieh Y.T., Schaefer P., Chae S., Klemm L., Huantes S., Loh M.,
Conway E.M., Kang E.S., Hoe Koo H., Hofmann W.K., Heisterkamp N., Pelus
L., Keerthivasan G., Crispino J., Kahn M., Muschen M. and Kim Y.M. (2011).
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.
Blood 118, 2191-2199.
Park J.A., Sharif A.S., Tschumperlin D.J., Lau L., Limbrey R., Howarth P. and Drazen
J.M. (2012). Tissue factor-bearing exosome secretion from human mechanically
stimulated bronchial epithelial cells in vitro and in vivo. The Journal of allergy
and clinical immunology 130, 1375-1383.
Park J.O., Choi D.Y., Choi D.S., Kim H.J., Kang J.W., Jung J.H., Lee J.H., Kim J.,
Freeman M.R., Lee K.Y., Gho Y.S. and Kim K.P. (2013). Identification and
characterization of proteins isolated from microvesicles derived from human lung
cancer pleural effusions. Proteomics 13, 2125-2134.
Parkin D.M., Bray F., Ferlay J. and Pisani P. (2005). Global cancer statistics, 2002. CA: a
cancer journal for clinicians 55, 74-108.
Perkins D.N., Pappin D.J., Creasy D.M. and Cottrell J.S. (1999). Probability-based
protein identification by searching sequence databases using mass spectrometry
data. Electrophoresis 20, 3551-3567.
Pernick N.L., Sarkar F.H., Philip P.A., Arlauskas P., Shields A.F., Vaitkevicius V.K.,
Dugan M.C. and Adsay N.V. (2003). Clinicopathologic analysis of pancreatic
adenocarcinoma in african americans and caucasians. Pancreas 26, 28-32.
Pietra G., Manzini C., Rivara S., Vitale M., Cantoni C., Petretto A., Balsamo M., Conte
R., Benelli R., Minghelli S., Solari N., Gualco M., Queirolo P., Moretta L. and
Mingari M.C. (2012). Melanoma cells inhibit natural killer cell function by
modulating the expression of activating receptors and cytolytic activity. Cancer
research 72, 1407-1415.

119

Ploussard G. and de la Taille A. (2010). Urine biomarkers in prostate cancer. Nature
reviews. Urology 7, 101-109.
Powell I.J., Vigneau F.D., Bock C.H., Ruterbusch J. and Heilbrun L.K. (2014). Reducing
prostate cancer racial disparity: Evidence for aggressive early prostate cancer psa
testing of african american men. Cancer epidemiology, biomarkers & prevention :
a publication of the American Association for Cancer Research, cosponsored by
the American Society of Preventive Oncology.
Properzi F., Logozzi M. and Fais S. (2013). Exosomes: The future of biomarkers in
medicine. Biomarkers in medicine 7, 769-778.
Pulte D., Redaniel M.T., Brenner H. and Jeffreys M. (2012). Changes in survival by
ethnicity of patients with cancer between 1992-1996 and 2002-2006: Is the
discrepancy decreasing? Annals of oncology : official journal of the European
Society for Medical Oncology / ESMO 23, 2428-2434.
Qin Q., Zhang C., Zhu H., Yang X., Xu L., Liu J., Lu J., Zhan L., Cheng H. and Sun X.
(2014). Association between survivin -31g>c polymorphism and cancer risk:
Meta-analysis of 29 studies. Journal of cancer research and clinical oncology 140,
179-188.
Quah B.J. and O'Neill H.C. (2005). The immunogenicity of dendritic cell-derived
exosomes. Blood Cells Mol Dis 35, 94-110.
Radojevic-Skodric S., Basta-Jovanovic G., Brasanac D., Nikolic N., Bogdanovic L.,
Milicic B. and Milasin J. (2012). Survivin gene promoter -31 g/c polymorphism is
associated with wilms tumor susceptibility in serbian children. Journal of
pediatric hematology/oncology 34, e310-314.
Reed J.C. (2001). The survivin saga goes in vivo. The Journal of Clinical Investigation
108, 965-969.
Rexhepaj E., Jirstrom K., O'Connor D., O'Brien S., Landberg G., Duffy M., Brennan D.
and Gallagher W. (2010). Validation of cytoplasmic-to-nuclear ratio of survivin
as an indicator of improved prognosis in breast cancer. BMC cancer 10, 639.
Rolfo C., Castiglia M., Hong D., Alessandro R., Mertens I., Baggerman G., Zwaenepoel
K., Gil-Bazo I., Passiglia F., Carreca A.P., Taverna S., Vento R., Peeters M.,
Russo A. and Pauwels P. (2014). Liquid biopsies in lung cancer: The new
ambrosia of researchers. Biochimica et biophysica acta 1846, 539-546.
Sagol O., Yavuzsen T., Oztop I., Ulukus C., Ylmaz U., Alakavuklar M., Karademir S.,
Obuz F., Astarcoglu H. and Astarcoglu I. (2005). The effect of apoptotic activity,
survivin, ki-67, and p-glycoprotein expression on prognosis in pancreatic
carcinoma. Pancreas 30, 343-348.

120

Saif M.W., Sviglin H. and Carpenter M. (2005). Impact of ethnicity on outcome in
pancreatic carcinoma. JOP 6, 246-254.
Savina A, Furlan M, Vidal M and Colombo MI. (2003). Exosome release is regulated by
a calcium-dependent mechanism in k562 cells. J Biol Chem 278, 20083-20090.
Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V.,
Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Berenguer
A., Maattanen L., Bangma C.H., Aus G., Villers A., Rebillard X., van der Kwast
T., Blijenberg B.G., Moss S.M., de Koning H.J., Auvinen A. and Investigators E.
(2009). Screening and prostate-cancer mortality in a randomized european study.
The New England journal of medicine 360, 1320-1328.
Shariat S.F., Semjonow A., Lilja H., Savage C., Vickers A.J. and Bjartell A. (2011).
Tumor markers in prostate cancer i: Blood-based markers. Acta Oncol 50 Suppl 1,
61-75.
Shariat S.F., Lotan Y., Saboorian H., Khoddami S.M., Roehrborn C.G., Slawin K.M. and
Ashfaq R. (2004). Survivin expression is associated with features of biologically
aggressive prostate carcinoma. Cancer 100, 751-757.
Shariat SF, Lothan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM and
Ashfaq R. (2004). Survivin expression is associated with features of biologically
aggressive prostate carcinoma. Cancer 100, 751-757.
Sharp L., Deady S., Gallagher P., Molcho M., Pearce A., Alforque Thomas A., Timmons
A. and Comber H. (2014). The magnitude and characteristics of the population of
cancer survivors: Using population-based estimates of cancer prevalence to
inform service planning for survivorship care. BMC cancer 14, 767.
Shen J., Liu J., Long Y., Miao Y., Su M., Zhang Q., Han H. and Hao X. (2009).
Knockdown of survivin expression by sirnas enhances chemosensitivity of
prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin
(Shanghai) 41, 223-230.
Shender V.O., Pavlyukov M.S., Ziganshin R.H., Arapidi G.P., Kovalchuk S.I., Anikanov
N.A., Altukhov I.A., Alexeev D.G., Butenko I.O., Shavarda A.L., Khomyakova
E.B., Evtushenko E., Ashrafyan L.A., Antonova I.B., Kuznetcov I.N., Gorbachev
A.Y., Shakhparonov M.I. and Govorun V.M. (2014). Proteome-metabolome
profiling of ovarian cancer ascites reveals novel components involved in
intercellular communication. Molecular & cellular proteomics : MCP 13, 35583571.
Siegel R., Naishadham D. and Jemal A. (2013). Cancer statistics, 2013. CA: a cancer
journal for clinicians 63, 11-30.
Siegel R., Ma J., Zou Z. and Jemal A. (2014). Cancer statistics, 2014. CA: a cancer
journal for clinicians 64, 9-29.
121

Simpson RJ, Lim JWE, Moritz RL and Mathivanan S. (2009). Exosomes: Proteomic
insights and diagnostic potential. Expert Rev Proteomic 6, 267-283.
Singal V., Singal A.K. and Kuo Y.F. (2012). Racial disparities in treatment for pancreatic
cancer and impact on survival: A population-based analysis. Journal of cancer
research and clinical oncology 138, 715-722.
Small S., Keerthivasan G., Huang Z., Gurbuxani S. and Crispino J.D. (2010).
Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia
24, 1920-1926.
Smith J.P., Harms J.F., Matters G.L., McGovern C.O., Ruggiero F.M., Liao J., Fino K.K.,
Ortega E.E., Gilius E.L. and Phillips J.A., 3rd. (2012). A single nucleotide
polymorphism of the cholecystokinin-b receptor predicts risk for pancreatic
cancer. Cancer Biol Ther 13, 164-174.
Smith J.R., Freije D., Carpten J.D., Gronberg H., Xu J., Isaacs S.D., Brownstein M.J.,
Bova G.S., Guo H., Bujnovszky P., Nusskern D.R., Damber J.E., Bergh A.,
Emanuelsson M., Kallioniemi O.P., Walker-Daniels J., Bailey-Wilson J.E., Beaty
T.H., Meyers D.A., Walsh P.C., Collins F.S., Trent J.M. and Isaacs W.B. (1996).
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a
genome-wide search. Science 274, 1371-1374.
Smith M.R., Klotz L., van der Meulen E., Colli E. and Tanko L.B. (2011). Gonadotropinreleasing hormone blockers and cardiovascular disease risk: Analysis of
prospective clinical trials of degarelix. J Urol 186, 1835-1842.
Society L.L. (2012). Facts and statistics. In. Leukemia & Lymphoma Society.
Span P.N., Tjan-Heijnen V.C.G., Manders P., van Tienoven D., Lehr J. and Sweep
F.C.G.J. (2006). High survivin predicts a poor response to endocrine therapy, but
a good response to chemotherapy in advanced breast cancer. Breast cancer
research and treatment 98, 223-230.
Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S. and Redwine E. (1987).
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
The New England journal of medicine 317, 909-916.
Sugahara K., Uemura A., Harasawa H., Nagai H., Hirakata Y., Tomonaga M., Murata K.,
Sohda H., Nakagoe T., Shibasaki S., Yamada Y. and Kamihira S. (2004). Clinical
relevance of survivin as a biomarker in neoplasms, especially in adult t-cell
leukemias and acute leukemias. Int J Hematol 80, 52-58.
Sun H.C., Qiu Z.J., Liu J., Sun J., Jiang T., Huang K.J., Yao M. and Huang C. (2007).
Expression of hypoxia-inducible factor-1 alpha and associated proteins in
pancreatic ductal adenocarcinoma and their impact on prognosis. International
journal of oncology 30, 1359-1367.

122

Takachi R., Tsubono Y., Baba K., Inoue M., Sasazuki S., Iwasaki M., Tsugane S. and
Japan Public Health Center-Based Prospective Study G. (2011). Red meat intake
may increase the risk of colon cancer in japanese, a population with relatively low
red meat consumption. Asia Pacific journal of clinical nutrition 20, 603-612.
Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T. and Reed J.C.
(1998). Iap-family protein survivin inhibits caspase activity and apoptosis induced
by fas (cd95), bax, caspases, and anticancer drugs. Cancer research 58, 53155320.
Tan H.T., Low J., Lim S.G. and Chung M.C. (2009). Serum autoantibodies as biomarkers
for early cancer detection. The FEBS journal 276, 6880-6904.
Tanaka M., Butler M.O., Ansén S., Imataki O., Berezovskaya A., Nadler L.M. and
Hirano N. (2011). Induction of hla-dp4–restricted anti-survivin th1 and th2
responses using an artificial antigen-presenting cell. Clinical Cancer Research 17,
5392-5401.
Tao S., Wang Z., Feng J., Hsu F.C., Jin G., Kim S.T., Zhang Z., Gronberg H., Zheng
L.S., Isaacs W.B., Xu J. and Sun J. (2012). A genome-wide search for loci
interacting with known prostate cancer risk-associated genetic variants.
Carcinogenesis 33, 598-603.
Tindall E.A., Monare L.R., Petersen D.C., van Zyl S., Hardie R.A., Segone A.M., Venter
P.A., Bornman M.S. and Hayes V.M. (2014). Clinical presentation of prostate
cancer in black south africans. The Prostate 74, 880-891.
Tjalsma H., Schaeps R.M. and Swinkels D.W. (2008). Immunoproteomics: From
biomarker discovery to diagnostic applications. Proteomics Clin Appl 2, 167-180.
Tong W.G., Ding X.Z., Witt R.C. and Adrian T.E. (2002). Lipoxygenase inhibitors
attenuate growth of human pancreatic cancer xenografts and induce apoptosis
through the mitochondrial pathway. Mol Cancer Ther 1, 929-935.
Tonini G., Vincenzi B., Santini D., Scarpa S., Vasaturo T., Malacrino C., Coppola R.,
Magistrelli P., Borzomati D., Baldi A., Antinori A., Caricato M., Nuzzo G. and
Picciocchi A. (2005). Nuclear and cytoplasmic expression of survivin in 67
surgically resected pancreatic cancer patients. Br J Cancer 92, 2225-2232.
Troeger A., Siepermann M., Escherich G., Meisel R., Willers R., Gudowius S., Moritz T.,
Laws H.J., Hanenberg H., Goebel U., Janka-Schaub G.E., Mahotka C. and Dilloo
D. (2007). Survivin and its prognostic significance in pediatric acute b-cell
precursor lymphoblastic leukemia. Haematologica 92, 1043-1050.
Tsai C.J. and Giovannucci E.L. (2012). Hyperinsulinemia, insulin resistance, vitamin d,
and colorectal cancer among whites and african americans. Digestive diseases and
sciences 57, 2497-2503.

123

Tyner J.W., Jemal A.M., Thayer M., Druker B.J. and Chang B.H. (2012). Targeting
survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia 26, 623632.
Valenti R., Huber V., Iero M., Filipazzi P., Parmiani G. and Rivoltini L. (2007). Tumorreleased microvesicles as vehicles of immunosuppression. Cancer research 67,
2912-2915.
Valenzuela M.M., Ferguson Bennit H.R., Gonda A., Diaz Osterman C.J., Hibma A.,
Khan S. and Wall N.R. (2015). Exosomes secreted from human cancer cell lines
contain inhibitors of apoptosis (iap). Cancer microenvironment : official journal
of the International Cancer Microenvironment Society.
Velculescu V.E., Madden S.L., Zhang L., Lash A.E., Yu J., Rago C., Lal A., Wang C.J.,
Beaudry G.A., Ciriello K.M., Cook B.P., Dufault M.R., Ferguson A.T., Gao Y.,
He T.C., Hermeking H., Hiraldo S.K., Hwang P.M., Lopez M.A., Luderer H.F.,
Mathews B., Petroziello J.M., Polyak K., Zawel L., Kinzler K.W. and et al.
(1999). Analysis of human transcriptomes. Nature genetics 23, 387-388.
Verma A., St Onge J., Dhillon K. and Chorneyko A. (2014). Psa density improves
prediction of prostate cancer. The Canadian journal of urology 21, 7312-7321.
Vlassov A.V., Magdaleno S., Setterquist R. and Conrad R. (2012). Exosomes: Current
knowledge of their composition, biological functions, and diagnostic and
therapeutic potentials. Biochimica et biophysica acta.
Waligorska-Stachura J., Jankowska A., Wasko R., Liebert W., Biczysko M.,
Czarnywojtek A., Baszko-Blaszyk D., Shimek V. and Ruchala M. (2012).
Survivin--prognostic tumor biomarker in human neoplasms--review. Ginekologia
polska 83, 537-540.
Wan Y.Y. (2010). Multi-tasking of helper t cells. Immunology 130, 166-171.
Wang Z., Sampath J., Fukuda S. and Pelus L.M. (2005). Disruption of the inhibitor of
apoptosis protein survivin sensitizes bcr-abl-positive cells to sti571-induced
apoptosis. Cancer research 65, 8224-8232.
Webber J., Yeung V. and Clayton A. (2015). Extracellular vesicles as modulators of the
cancer microenvironment. Seminars in cell & developmental biology.
Welsh J.B., Sapinoso L.M., Kern S.G., Brown D.A., Liu T., Bauskin A.R., Ward R.L.,
Hawkins N.J., Quinn D.I., Russell P.J., Sutherland R.L., Breit S.N., Moskaluk
C.A., Frierson H.F., Jr. and Hampton G.M. (2003). Large-scale delineation of
secreted protein biomarkers overexpressed in cancer tissue and serum.
Proceedings of the National Academy of Sciences of the United States of America
100, 3410-3415.

124

Werny D.M., Thompson T., Saraiya M., Freedman D., Kottiri B.J., German R.R. and
Wener M. (2007). Obesity is negatively associated with prostate-specific antigen
in u.S. Men, 2001-2004. Cancer epidemiology, biomarkers & prevention : a
publication of the American Association for Cancer Research, cosponsored by the
American Society of Preventive Oncology 16, 70-76.
Wieckowski E and TL W. (2006). Human tumor-derived vs dendritic cell-derived
exosomes have distinct biologic roles and molecular profiles. Immunologic
Research 36, 247-254.
Williams R.M. and Naz R.K. (2010). Novel biomarkers and therapeutic targets for
prostate cancer. Front Biosci (Schol Ed) 2, 677-684.
Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux
S, Faure F, Tursz T, Angevin E, Amigorena S and Zitvogel L. (2001). Tumorderived exosomes are a source of shared tumor rejection antigens for ctl crosspriming. Nat Med 7, 297-303.
Woutersen R.A., Appel M.J., van Garderen-Hoetmer A. and Wijnands M.V. (1999).
Dietary fat and carcinogenesis. Mutation research 443, 111-127.
Xie H., Jiang W., Xiao S.-Y. and Liu X. (2013). High expression of survivin is
prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit
in patients with resected pancreatic adenocarcinoma. Journal of Histochemistry &
Cytochemistry 61, 148-155.
Xing Z., Conway E.M., Kang C. and Winoto A. (2004). Essential role of survivin, an
inhibitor of apoptosis protein, in t cell development, maturation, and homeostasis.
The Journal of Experimental Medicine 199, 69-80.
Xu C., Yamamoto-Ibusuki M., Yamamoto Y., Yamamoto S., Fujiwara S., Murakami K.,
Okumura Y., Yamaguchi L., Fujiki Y. and Iwase H. (2012). High survivin mrna
expression is a predictor of poor prognosis in breast cancer: A comparative study
at the mrna and protein level. Breast Cancer 1-9.
Yang C. and Robbins P.D. (2011). The roles of tumor-derived exosomes in cancer
pathogenesis. Clinical & developmental immunology 2011, 842849.
Yang D., Welm A. and Bishop J.M. (2004). Cell division and cell survival in the absence
of survivin. Proceedings of the National Academy of Sciences of the United
States of America 101, 15100-15105.
Yang Z., Wang L., Wang H., Shang X., Niu W., Li J. and Wu Y. (2008). A novel
mimovirus vaccine containing survivin epitope with adjuvant il-15 induces longlasting cellular immunity and high antitumor efficiency. Molecular Immunology
45, 1674-1681.

125

Ye H., Pungpravat N., Huang B.L., Muzio L.L., Mariggio M.A., Chen Z., Wong D.T. and
Zhou X. (2007). Genomic assessments of the frequent loss of heterozygosity
region on 8p21.3-p22 in head and neck squamous cell carcinoma. Cancer genetics
and cytogenetics 176, 100-106.
Zaffaroni N., Pannati M. and Diadone M.G. (2005). Survivin as a target for new
anticancer interventions. Journal of Cellular and Molecular Medicine 9, 360-372.
Zagorska A. and Dulak J. (2004). Hif-1: The knowns and unknowns of hypoxia sensing.
Acta Biochim Pol 51, 563-585.
Zangemeister-Wittke U. and Simon H.-U. (2004). An iap in action: The multiple roles of
survivin in differentiation, immunity and malignancy. Cell Cycle 3, 1119-1121.
Zhang M., Ho A., Hammond E.H., Suzuki Y., Bermudez R.S., Lee R.J., Pilepich M.,
Shipley W.U., Sandler H., Khor L.-Y., Pollack A. and Chakravarti A. (2009).
Prognostic value of survivin in locally advanced prostate cancer: Study based on
rtog 8610. International Journal of Radiation Oncology*Biology*Physics 73,
1033-1042.
Zhang M, Latham DE, Delaney MA and Chakravarti A. (2005). Survivin mediates
resistance to antiandrogen therapy in prostate cancer. Oncogene 24, 2474-2482.
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli
P, Raposo G and Amigorena S. (1998). Eradication of established murine tumors
using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 4, 594600.

126

Dr. David Turay’s BIOGRAPHICAL SKETCH
Position Title:
Assistant Professor of Surgery, Chief – Division of Acute Care Surgery, Dept of
Surgery
Education and Training:
Institution
Universidad de Montemorelos
Loma Linda University
Loma Linda University
Massachusetts General Hospital
Harvard Medical School
Loma Linda University

Year
1999
2005-2006
2006-2010
2013-2014

Field of Study
Degree
Medicine
MD
Internship, Gen. Surgery
Resident, Gen. Surgery
Fellowship, Critical Care Surg

2010-2016

Anatomy

PhD

A. Personal Statement
My desire to be grounded in the Basic Sciences and my realization of the increasing
role of Molecular Medicine in the treatment of multiple conditions, led me back to the
lab. My mentor and friend Dr. Nathan Wall was kind enough to open the doors of his
Laboratory to me and in so doing, opened my eyes to a whole new reality of Cancer
Biology and biomarker molecular biology. I initially wondered how this will fit into my
current clinical interest in caring for the injured and those with critical illness. It was at
Dr. Wall’s Lab that I came to increasingly see some similarities between cancer; a final
pathway to chronic disordered inflammation and the inflammatory process that
inevitably follows injury. In this research project, we set out to discover novel
extracellular (exosomal) biomarkers and their role in resistance of cancers to stressinduced cell death in the tumor microenvironment. I intend to eventually apply the
knowledge gained in this endeavor to examine serum exosomes of head injury patients
for biomarkers of therapeutic and prognostic significance. I am uniquely prepared and
delighted to work with Dr. Wall and this group on the translational phase of his
important research.
B. Positions/Appointments
07/2015 – Present
Division Chief, Acute Care Surgery
Medical Director of Trauma Services

Loma Linda Univ.
Medical Center

07/2014 – Present

Associate Director, Surgical
Intensive Care Unit

Loma Linda Univ.
Medical Center

07/2010 –06/2013

Attending Surgeon & Assistant
Professor of Surgery

Loma Linda Univ.
Medical Center

Community Health Officer
(Required for MD degree)

El Camaron
Municipality

C. Prior
Positions
07/1998 –06/1999

127

07/1989 –08/1991

Math and Science Teacher

Oaxaca, Mexico
Masanga Primary
School
Masanga, Sierra
Leone

D. Honors and Awards
2013
Clinical Teacher of the year
Loma Linda University
2010
Teaching Resident of the year
Loma Linda University
2010
Alpha Omega Alpha
Loma Linda University
2009
Vascular Surgery Senior Resident of the year
Loma Linda University
1994
Best Student in the Basic Sciences
Universidad de Montemorelos
1987
Student of the year in Chemistry and Mathematics Award
Christ the King College, Sierra Leone
E. Memberships in professional Organizations
2013
Society of Critical Care Medicine
2013
Massachusetts Medical Society
2012
Society of American Gastrointestinal and Endoscopic Surgeons
2010
Alpha Omega Alpha Honor Medical Society
2006
American College of Surgeons (Current Fellow)
2005
American Association of Anatomists
F. Boards & Certifications
09/2014
Surgical Critical Care (Subspecialty of the American Board of Surgery)
02/2011
American Board of General Surgery
07/2014
Advance Trauma Life Support Instructor
06/2011
Fluoroscopy and X-Ray Supervisor and Operator
05/2010
Fundamentals of Laparoscopic Surgery
02/2009
Advanced Cardiac Life Support – Experienced Provider
09/2006
Advance Trauma Life Support
03/2000
Educational Commission for Foreign Medical Graduates
G. Current Professional State Licenses
06/2007
Physician & Surgeon’s License, Medical Board of California
07/2013
Physicians License, Commonwealth of Massachusetts Board of
Medicine
H. Selected recent and relevant peer-reviewed publications
Turay D, Khan S, Osterman CD, Curtis MP, Khaira B, Neidigh JW, Mirshahidi S,
Casiano CA, Wall NR. Proteomic profiling of serum-derived exosomes from
128

ethnically diverse prostate cancer patients. Accepted for Publication, Cancer
Investigation, 2015.
Khan S, Ferguson Bennit H, Valenzuela MMA, Turay D, Diaz Osterman CJ, Moyron
RB, Esebanmen GE, Ashok A, Wall NR. Localization and up regulation of
Survivin in cancer health disparities: a clinical perspective. Biologics: Targets and
Therapy, 9: 57-67, 2015.
Khan S, Jutzy JMS, Aspe JR, Valenzuela MMA, Park J, Turay D, Wall NR. The
Application of Membrane Vesicles for Cancer Therapy. Book 3, Advances in
Cancer Therapy, InTech Publishing 2011, ISBN 978-953-307-703-1.
Khan S, Jutzy JMS, Valenzuela MMA, Turay D, Aspe JR, Ashok A, Mirshahidi S,
Mercola D, Lilly MB, Wall NR. Plasma-Derived Exosomal Survivin, a Plausible
Biomarker for Early Detection of Prostate Cancer. PLoS One, 7(10): 1-10, 2012.
Khan S, Ferguson H, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. Early
diagnostic value of Survivin and its alternative splice variants in breast cancer.
BMC Cancer, 14(1):176, 2014.

129

